<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews - Mourad, S - 2017 | Cochrane Library</title> <meta content="Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews - Mourad, S - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012103.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews - Mourad, S - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012103.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012103.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews" name="citation_title"/> <meta content="Selma Mourad" name="citation_author"/> <meta content="Radboud University Medical Centre" name="citation_author_institution"/> <meta content="Selma.Mourad@radboudumc.nl" name="citation_author_email"/> <meta content="Julie Brown" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Cindy Farquhar" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD012103.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/01/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012103.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012103.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012103.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cabergoline; Ergolines [therapeutic use]; Gonadotropin-Releasing Hormone [agonists, therapeutic use]; Metformin [therapeutic use]; Ovarian Hyperstimulation Syndrome [etiology, *prevention &amp; control, therapy]; Progesterone [therapeutic use]; Reproductive Techniques, Assisted [*adverse effects]; Review Literature as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012103.pub2&amp;doi=10.1002/14651858.CD012103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012103\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012103\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012103.pub2",title:"Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews",firstPublishedDate:"Jan 23, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012103.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012103.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012103.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012103.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012103.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012103.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012103.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012103.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012103.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012103.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6156 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012103.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-sec-0076"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-sec-0020"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-sec-0021"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-sec-0036"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-sec-0070"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/appendices#CD012103-sec-0081"> Search strategies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Overview</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/information#CD012103-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Selma Mourad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/information#CD012103-cr-0003">Julie Brown</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012103.pub2/information#CD012103-cr-0004">Cindy Farquhar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/information/en#CD012103-sec-0088">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 January 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012103.pub2">https://doi.org/10.1002/14651858.CD012103.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012103-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012103-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012103-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012103-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012103-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012103-abs-0001" lang="en"> <section id="CD012103-sec-0001"> <h3 class="title" id="CD012103-sec-0001">Background</h3> <p>Ovarian hyperstimulation syndrome (OHSS) in assisted reproductive technology (ART) cycles is a treatment‐induced disease that has an estimated prevalence of 20% to 33% in its mild form and 3% to 8% in its moderate or severe form. These numbers might even be higher for high‐risk women such as those with polycystic ovaries or a high oocyte yield from ovum pickup. </p> </section> <section id="CD012103-sec-0002"> <h3 class="title" id="CD012103-sec-0002">Objectives</h3> <p>The objective of this overview is to identify and summarise all evidence from Cochrane systematic reviews on interventions for prevention or treatment of moderate, severe and overall OHSS in couples with subfertility who are undergoing ART cycles. </p> </section> <section id="CD012103-sec-0003"> <h3 class="title" id="CD012103-sec-0003">Methods</h3> <p>Published Cochrane systematic reviews reporting on moderate, severe or overall OHSS as an outcome in ART cycles were eligible for inclusion in this overview. We also identified Cochrane submitted protocols and title registrations for future inclusion in the overview. The evidence is current to 12 December 2016. We identified reviews, protocols and titles by searching the Cochrane Gynaecology and Fertility Group Database of Systematic Reviews and Archie (the Cochrane information management system) in July 2016 on the effectiveness of interventions for outcomes of moderate, severe and overall OHSS. We undertook in duplicate selection of systematic reviews, data extraction and quality assessment. We used the AMSTAR (Assessing the Methodological Quality of Systematic Reviews) tool to assess the quality of included reviews, and we used GRADE methods to assess the quality of the evidence for each outcome. We summarised the characteristics of included reviews in the text and in additional tables. </p> </section> <section id="CD012103-sec-0004"> <h3 class="title" id="CD012103-sec-0004">Main results</h3> <p>We included a total of 27 reviews in this overview. The reviews were generally of high quality according to AMSTAR ratings, and included studies provided evidence that ranged from very low to high in quality. Ten reviews had not been updated in the past three years. Seven reviews described interventions that provided a beneficial effect in reducing OHSS rates, and we categorised one additional review as 'promising'. Of the effective interventions, all except one had no detrimental effect on pregnancy outcomes. </p> <p><i>Evidence of at least moderate quality</i> indicates that clinicians should consider the following interventions in ART cycles to reduce OHSS rates. </p> <p>• Metformin treatment before and during an ART cycle for women with PCOS (moderate‐quality evidence). </p> <p>• Gonadotrophin‐releasing hormone (GnRH) antagonist protocol in ART cycles (moderate‐quality evidence). </p> <p>• GnRH agonist (GnRHa) trigger in donor oocyte or 'freeze‐all' programmes (moderate‐quality evidence). </p> <p><i>Evidence of low or very low quality</i> suggests that clinicians should consider the following interventions in ART cycles to reduce OHSS rates. </p> <p>• Clomiphene citrate for controlled ovarian stimulation in ART cycles (low‐quality evidence). </p> <p>• Cabergoline around the time of human chorionic gonadotrophin (hCG) administration or oocyte pickup in ART cycles (low‐quality evidence). </p> <p>• Intravenous fluids (plasma expanders) around the time of hCG administration or oocyte pickup in ART cycles (very low‐quality evidence). </p> <p>• Progesterone for luteal phase support in ART cycles (low‐quality evidence).</p> <p>• Coasting (withholding gonadotrophins) ‐ a promising intervention that needs to be researched further for reduction of OHSS. </p> <p>On the basis of this overview, we must conclude that evidence is currently insufficient to support the widespread practice of embryo cryopreservation. </p> </section> <section id="CD012103-sec-0005"> <h3 class="title" id="CD012103-sec-0005">Authors' conclusions</h3> <p>Currently, 27 reviews in the Cochrane Library were conducted to report on or to try to report on OHSS in ART cycles. We identified four review protocols but no new registered titles that can potentially be included in this overview in the future. This overview provides the most up‐to‐date evidence on prevention of OHSS in ART cycles from all currently published Cochrane reviews on ART. Clinicians can use the evidence summarised in this overview to choose the best treatment regimen for individual patients ‐ a regimen that not only reduces the chance of developing OHSS but does not compromise other outcomes such as pregnancy or live birth rate. Review results, however, are limited by the lack of recent primary studies or updated reviews. Furthermore, this overview can be used by policymakers in developing local and regional protocols or guidelines and can reveal knowledge gaps for future research. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012103-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012103-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012103-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012103-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012103-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012103-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012103-abs-0004" lang="en"> <h3>Interventions for prevention of ovarian hyperstimulation syndrome in in vitro fertilisation cycles: an overview of Cochrane reviews </h3> <p><b>Overview question</b> </p> <p>This overview of Cochrane reviews aims to identify and summarise all evidence from Cochrane systematic reviews on interventions that could prevent or treat moderate, severe and overall ovarian hyperstimulation syndrome (OHSS) in couples with subfertility who are undergoing assisted reproductive technology (ART) cycles (i.e. in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI)). </p> <p><b>Background</b> </p> <p>OHSS in ART cycles is an adverse event that follows ovarian stimulation for IVF. It is caused by a very high ovarian response to hormonal medication and results in enlarged ovaries and a fluid shift from blood vessels to the abdominal cavity, resulting in, for example, abdominal bloating, high risk of clots within the blood vessels (thrombosis) and decreased blood supply to important organs such as kidneys and liver. The mild form of OHSS is seen in almost 20% to 33% of cycles, whereas a moderate or severe form is found in approximately 3% to 8% of cycles and can lead to serious disease burden or even mortality if left untreated. It is therefore important to identify treatment regimens and interventions that can reduce the incidence of OHSS. </p> <p><b>Study characteristics</b> </p> <p>We found a total of 27 Cochrane ART reviews of high quality that could be included for this overview. These reviews aimed to report on OHSS in cycles of IVF or ICSI. We did not include reviews of intrauterine insemination and ovulation induction. The evidence is current to 12 December 2016. </p> <p><b>Key results</b> </p> <p>Of the 27 reviews included in this overview, 10 reviews had not been updated in the past three years. </p> <p>Seven reviews described interventions that provided a beneficial effect in reducing OHSS rates, and we categorised one additional review as 'promising'. Of the effective interventions, all except one had no detrimental effect on pregnancy outcomes. <i>Evidence of at least moderate quality evidence</i> indicates that clinicians should consider the following interventions in ART cycles to reduce OHSS rates. </p> <p>• Metformin treatment before and during an ART cycle in women with PCOS (moderate‐quality evidence). </p> <p>• Gonadotrophin‐releasing hormone (GnRH) antagonist protocol in ART cycles (moderate‐quality evidence). </p> <p>• GnRH agonist (GnRHa) trigger in donor oocyte or 'freeze‐all' programmes (moderate‐quality evidence). </p> <p><i>Evidence of low or very low quality evidence</i> suggests that clinicians should consider the following interventions in ART cycles to reduce OHSS rates. </p> <p>• Clomiphene citrate for controlled ovarian stimulation in ART cycles (low‐quality evidence). </p> <p>• Cabergoline around the time of human chorionic gonadotrophin (hCG) administration or oocyte pickup in ART cycles (low‐quality evidence). </p> <p>• Intravenous fluids (blood plasma expanders) around the time of hCG administration or egg pickup in ART cycles (very low‐quality evidence). </p> <p>• Progesterone for luteal phase support in ART cycles (low‐quality evidence).</p> <p>A promising intervention that needs to be researched further is coasting (withholding gonadotrophins) for reduction of OHSS. On the basis of this overview, we must conclude that evidence is currently insufficient to support the widespread practice of freezing all embryos and replacing them at a later time when OHSS has dissolved. </p> <p>Clinicians can use the evidence summarised in this overview to choose the best treatment regimen for individual patients ‐ a regimen that not only reduces the chance of developing OHSS but does not compromise pregnancy outcomes. However, results of this overview are limited by the lack of recent primary studies or updated reviews. Furthermore, this overview can be used by policymakers in developing local and regional protocols or guidelines and can reveal knowledge gaps for future research. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012103-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012103-sec-0076"></div> This overview provides the most up‐to‐date evidence on prevention of OHSS in ART cycles from all currently published Cochrane reviews on ART. Clinicians can use the evidence summarised in this overview to choose the best treatment regimen for individual patients: a regimen that not only reduces the chance of developing OHSS but does not compromise other outcomes such as pregnancy or live birth rate. Furthermore, policymakers can use this overview when developing local and regional protocols or guidelines, and investigators can use it to identify knowledge gaps for future research. <section id="CD012103-sec-0077"> <p> <h5 class="title">Implications for practice</h5> <section id="CD012103-sec-0078"> <p><i>Evidence of at least moderate quality</i> shows that clinicians should consider the following interventions to reduce OHSS rates in ART cycles. </p> <p> <ul id="CD012103-list-0028"> <li> <p>Metformin treatment before and during an ART cycle for women with PCOS (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a>). </p> </li> <li> <p>Dopamine agonists around the time of hCG administration or oocyte pickup in ART cycles (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a>). </p> </li> <li> <p>GnRH antagonist protocol in ART cycles (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a>). </p> </li> <li> <p>GnRHa trigger in donor oocyte or 'freeze‐all' programmes, as it reduces OHSS and leads to lower pregnancy rates when embryo transfer is performed in the same cycle (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a>). </p> </li> </ul> </p> <p>All of the above mentioned interventions are preventive measures used to reduce OHSS rates. </p> <p><i>Evidence of low or very low quality</i> indicates that clinicians can consider the following interventions to reduce OHSS rates in ART cycles. </p> <p> <ul id="CD012103-list-0029"> <li> <p>Clomiphene citrate for controlled ovarian stimulation in ART cycles (low‐quality evidence) (<a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a>). </p> </li> <li> <p>Intravenous fluids (plasma expanders) around the time of hCG administration or oocyte pickup in ART cycles (very low‐quality evidence) (<a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a>). </p> </li> <li> <p>Progesterone for luteal phase support in ART cycles (low‐quality evidence) (<a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a>). </p> </li> </ul> </p> <p>Among the interventions mentioned above, clomiphene for ovarian stimulation and progesterone for luteal support are preventive measures used to reduce OHSS rates; dopamine agonists and plasma expanders are considered treatments for women with OHSS. </p> <p>On the basis of this overview, we must conclude that evidence is currently insufficient to support the widespread practice of embryo cryopreservation and coasting (withholding of gonadotrophins) for reduction of OHSS (<a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a>; <a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a>). </p> </section> </p> <p> <h5 class="title">Implications for research</h5> <section id="CD012103-sec-0079"> <p>This overview clearly identifies ways in which current evidence on effectiveness of interventions for prevention of OHSS is lacking. First, it highlights the need for review authors to update existing ART reviews to decrease knowledge gaps on this topic. Second, it should motivate clinicians and researchers to generate larger RCTs of higher quality to perform comparisons of new and existing interventions intended to reduce the incidence of OHSS. </p> <p>The following three interventions have been shown to reduce OHSS on the basis of low‐quality or very low‐quality evidence. The fourth intervention listed here has shown a <i>promising</i> effect on reduction of OHSS and should be prioritised for examination by researchers in new high‐quality RCTs. </p> <p> <ul id="CD012103-list-0030"> <li> <p>Clomiphene citrate for controlled ovarian stimulation in ART cycles (low‐quality evidence) (<a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a>). </p> </li> <li> <p>Intravenous fluids (plasma expanders) around the time of hCG administration or oocyte pickup in ART cycles (very low‐quality evidence) (<a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a>). </p> </li> <li> <p>Progesterone for luteal phase support in ART cycles (low‐quality evidence) (<a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a>). </p> </li> </ul> <ul id="CD012103-list-0031"> <li> <p>Coasting (withholding gonadotrophins) before hCG triggering in ART cycles (very low‐quality evidence) (<a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a>). </p> </li> </ul> </p> <p>The uptake of subgroups 'moderate' and 'severe' OHSS in outcome reporting would be very useful for future studies and reviews, as these categories are the most clinically significant subgroups of OHSS. Reporting these subgroups separately provides clinicians and policymakers with a far more balanced reflection of treatment risks than is provided by mere use of the outcome 'total OHSS', which also includes mild OHSS and might not be as clinically important. Furthermore, clinicians would benefit if new RCTs would distinguish early and late types of OHSS, as the time of development of OHSS could influence the choice of therapy. </p> <p>Large, well‐conducted RCTs are urgently needed to support the current evidence base for interventions described in this overview, including dose‐finding studies and research to determine the optimal timing of interventions. These trials should first examine interventions that seem to be effective but for which only very low‐quality, low‐quality or moderate‐quality evidence is available (<a href="#CD012103-tbl-0004">Table 4</a>). </p> </section> </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012103-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012103-sec-0016"></div> <section id="CD012103-sec-0017"> <h3 class="title" id="CD012103-sec-0017">Description of the condition</h3> <p>Ovarian hyperstimulation syndrome (OHSS) is a serious complication of controlled ovarian hyperstimulation cycles used in assisted reproductive technologies (ART). OHSS is clinically characterised by abdominal tenderness and swelling due to increased ovarian volume along with a sudden increase in vascular permeability, which results in a shift of fluid to the extravascular space. However, the exact pathophysiology of OHSS has not been completely elucidated. Cases of spontaneous OHSS have been reported and are suspected to be linked to follicle‐stimulating hormone (FSH) receptor gene mutations (<a href="./references#CD012103-bbs2-0069" title="DelbaereA , SmitsG , OlatunbosunO , PiersonR , VassartG , CostagliolaS . New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?. Human Reproduction2004;19(3):486‐9. ">Delbaere 2004</a>). However, the development of OHSS during ART cycles is mainly an iatrogenic side effect of the high doses of gonadotropin used for ovarian stimulation, resulting in multi‐follicular growth. A key role is suspected for vascular endothelial growth factor (VEGF), which is produced by multiple follicles following ovarian stimulation (<a href="./references#CD012103-bbs2-0063" title="AgrawalR , TanSL , WildS , SladkeviciusP , EngmannL , PayneN , et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertility and Sterility1999;71(2):287–93. ">Agrawal 1999</a>). Higher VEGF levels induce hyperpermeability of ovarian blood vessels, which leads to a fluid shift from the intravascular to the third space. Also, the administration of human chorionic gonadotrophin (hCG) as an ovulation trigger or luteal phase support in high‐risk women with extensive luteinisation and supraphysiological levels of oestradiol and progesterone in the presence of multiple corpora lutea can trigger OHSS (<a href="./references#CD012103-bbs2-0070" title="DelbaereA , SmitsG , DeLeenerA , CostagliolaS , VassartG . Understanding ovarian hyperstimulation syndrome. Endocrine2005;26(3):285‐90. ">Delbaere 2005</a>). Moreover, the extra hCG‐rise accompanying (multiple) pregnancy after ART can aggravate already existing OHSS or induce late‐onset OHSS. </p> <p>Over the years, several criteria have been used to classify OHSS severity (<a href="./appendices#CD012103-sec-0082">Appendix 1</a>; <a href="./references#CD012103-bbs2-0061" title="AboulgharMA , MansourRT . Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Human Reproduction Update2003;9(3):275‐89. ">Aboulghar 2003</a>; <a href="./references#CD012103-bbs2-0073" title="GolanA , Ron‐ElR , HermanA , SofferY , WainraubZ , CaspiE . Ovarian hyperstimulation syndrome: an update review. Obstetrical and Gynecological Survey1989;44(6):430‐40. ">Golan 1989</a>; <a href="./references#CD012103-bbs2-0085" title="NavotD , BerghPA , LauferN . Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility1992;58(2):249‐61. ">Navot 1992</a>; <a href="./references#CD012103-bbs2-0088" title="SchenkerJG , WeinsteinD . Ovarian hyperstimulation syndrome: a current survey. Fertility and Sterility1978;30(3):255‐68. ">Schenker 1978</a>). In general, when OHSS progresses to a moderate stage, women experience abdominal pain and nausea and vomiting, and ascites can be seen around the ovaries on vaginal ultrasonography. If the condition progresses to severe OHSS, extravascular fluid can be found in pleural and pericardial spaces, and several haemodynamic changes take place, such as intravascular volume depletion, haemoconcentration, hypoalbuminaemia and electrolyte imbalances. These changes can lead to severe morbidity associated with thromboembolic events (<a href="./references#CD012103-bbs2-0092" title="StewartJA , HamiltonPJ , MurdochAP . Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Human Reproduction1997;12(10):2167‐73. ">Stewart 1997</a>), respiratory distress and liver or renal failure. If left untreated, OHSS demonstrates rapid progression, with potentially life‐threatening or lethal complications (<a href="./references#CD012103-bbs2-0067" title="BraatD , BernardusR , GerrisJ . Anonymous reports of lethal cases of ovarian hyperstimulation syndrome. In: GerrisJ , OlivennesF , DelvigneA editor(s). Ovarian Hyperstimulation Syndrome. London: Informa UK Limited, 2006:59‐66. ">Braat 2006</a>). </p> <p>The mild form of OHSS is common, is of less clinical importance and occurs in an estimated 20% to 33% of ART cycles. The more clinically relevant moderate and severe forms of OHSS occur in an estimated 3% to 8% of ART cycles (3% to 6% moderate and 0.5% to 5% severe forms) (<a href="./references#CD012103-bbs2-0071" title="DelvigneA , RozenbergS . Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update2002;8(6):559‐77. ">Delvigne 2002</a>; <a href="./references#CD012103-bbs2-0073" title="GolanA , Ron‐ElR , HermanA , SofferY , WainraubZ , CaspiE . Ovarian hyperstimulation syndrome: an update review. Obstetrical and Gynecological Survey1989;44(6):430‐40. ">Golan 1989</a>; <a href="./references#CD012103-bbs2-0089" title="SchenkerJG , EzraY . Complications of assisted reproductive techniques. Fertility and Sterility1994;61(3):411‐22. ">Schenker 1994</a>). These large differences in reported OHSS incidence occur mainly because most reports involve single‐centre data, use different definitions of OHSS, do not require that diagnosis must be ascertained by a formal classification system or must have adequate follow‐up and lack reporting of mild or moderate forms. A large European report on 2010 ART practice (<a href="./references#CD012103-bbs2-0081" title="KupkaMS , FerrarettiAP , deMouzonJ , ErbK , D'HoogheT , CastillaJA , et al. Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE. Human Reproduction2014;29(10):2099‐113. ">Kupka 2014</a>) provided OHSS data for 25 participating countries and revealed prevalence of 0.3% in 349,402 simulated ART cycles. However, this report lacked data for some countries with a high volume of ART cycles (e.g. France, Sweden, the Netherlands, UK) and for other countries reported extremely low rates of OHSS, possibly as the result of reporting bias. A large Swiss retrospective cohort study reported a decline in OHSS incidence from 3.6% to 1% from 2005 to 2009 (<a href="./references#CD012103-bbs2-0068" title="DeGeyterC , FehrP , MoffatR , GruberIM , vonWolffM . Twenty years' experience with the Swiss data registry for assisted reproductive medicine: outcomes, key trends and recommendations for improved practice. Swiss Medical Weekly2015;145:w14087. [DOI: 10.4414/smw.2015.14087] ">De Geyter 2015</a>). Globally, the incidence of OHSS is declining; a steady decrease has been reported since its peak incidence in the 1990s, when the main goal of ART was to produce a high number of oocytes (<a href="./references#CD012103-bbs2-0080" title="KolS . Ovarian hyperstimulation syndrome prevention. Global Library of Women's Medicine,2011. [DOI: 10.3843/GLOWM.10466; ISSN:1756‐2228] ">Kol 2011</a>), and the incidence of severe OHSS was considered to be around 0.2% to 1% (<a href="./references#CD012103-bbs2-0062" title="AbramovY , ElchalalU , SchenkerJG . Severe OHSS: an 'epidemic' of severe OHSS: a price we have to pay?. Human Reproduction1999;14(9):2181‐3. ">Abramov 1999</a>). With the emergence of new treatment regimens, more judicious use of gonadotrophins, increased cycle monitoring and improved knowledge of OHSS risks, the incidence of this disorder fell gradually over subsequent decades. </p> <p>Although it is relatively rare, OHSS in ART cycles is an iatrogenic disease, and women who are affected should be monitored carefully to avoid life‐threatening complications. Early recognition of risk factors for OHSS can help clinicians tailor treatment regimens. Women with a priori risk for development of OHSS are those with polycystic ovaries (PCOs) (with or without PCO syndrome (PCOS)) or a high antral follicle count (e.g. at a young age). During a controlled ovarian stimulation cycle, women can acquire 'high risk' status when they prove to have high oestradiol levels, excessive growth of follicles or a large number of retrieved oocytes. Besides the early OHSS type that develops during, or immediately after, ovarian stimulation, we can distinguish a late type, which appears after embryo implantation has been established. The presence of a multiple gestation can trigger or exacerbate this late type of OHSS (<a href="./references#CD012103-bbs2-0070" title="DelbaereA , SmitsG , DeLeenerA , CostagliolaS , VassartG . Understanding ovarian hyperstimulation syndrome. Endocrine2005;26(3):285‐90. ">Delbaere 2005</a>; <a href="./references#CD012103-bbs2-0084" title="MathurRS , AkandeAV , KeaySD , HuntLP , JenkinsJM . Distinction between early and late ovarian hyperstimulation syndrome. Fertility and Sterility2000;73(5):901‐7. ">Mathur 2000</a>). </p> <section id="CD012103-sec-0018"> <h4 class="title">Description of interventions and how the interventions might work</h4> <p>Interventions that aim to reduce OHSS incidence can target diverse portions of stimulated ART cycles. </p> <p> <ul id="CD012103-list-0001"> <li> <p>Selection or identification of 'high risk' populations for tailoring of stimulation regimens. </p> </li> <li> <p>Prevention of recurrent OHSS by adjustment of the dose of gonadotrophins in the next cycle. </p> </li> <li> <p>Prevention of large numbers of follicles by tailored ovarian stimulation for specific risk groups (e.g. use of different treatment regimens, use of adjuvant medication). </p> </li> <li> <p>Prevention of a rise in VEGF levels (e.g. by prevention of development of large numbers of follicles, by targeting of VEGF receptors (e.g. by dopamine agonists)). </p> </li> <li> <p>Dose reduction or withholding of hCG administration for ovulation trigger or luteal support. </p> </li> <li> <p>Prevention of a rise in oestradiol by withholding of gonadotrophins (‘coasting’).</p> </li> <li> <p>Prevention of a further rise in oestradiol and of ovulation triggering and pregnancy by cycle cancellation. </p> </li> <li> <p>Prevention of intravascular volume depletion by administration of plasma‐expanding intravenous (IV) fluids. </p> </li> <li> <p>Prevention of pregnancy by freezing of all embryos and transfer back during a subsequent cycle. </p> </li> </ul> </p> <p>Moreover, trials of interventions within an ART cycle that are not specifically aimed at preventing OHSS may report on OHSS as an outcome. These interventions are of interest to this overview and might reveal new mechanisms for lowering risk of OHSS. </p> </section> </section> <section id="CD012103-sec-0019"> <h3 class="title" id="CD012103-sec-0019">Why it is important to do this overview</h3> <p>OHSS is an iatrogenic disease with an estimated incidence of 3% to 6% in ART cycles of the clinically relevant moderate or severe form (<a href="./references#CD012103-bbs2-0071" title="DelvigneA , RozenbergS . Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update2002;8(6):559‐77. ">Delvigne 2002</a>). If left untreated, OHSS can lead to severe morbidity and can be life‐threatening. Multiple treatment options are available for prevention of OHSS in ART cycles; therefore, it is important to provide consumers, health professionals, policymakers and guideline developers with a summary of evidence on OHSS prevention obtained from the Cochrane Library. We will comment upon this evidence in light of the overall effectiveness of studied interventions in the separate reviews. By doing so, we will identify existing knowledge gaps or reporting flaws within the Cochrane systematic reviews published in the Cochrane Library on the topic of OHSS in ART cycles. This means that we can provide clear suggestions for future research. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012103-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012103-sec-0020"></div> <p>The objective of this overview is to identify and summarise all evidence from Cochrane systematic reviews on interventions for prevention or treatment of moderate, severe and overall OHSS in couples with subfertility who are undergoing ART cycles. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012103-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012103-sec-0021"></div> <section id="CD012103-sec-0022"> <h3 class="title">Criteria for considering reviews for inclusion</h3> <section id="CD012103-sec-0023"> <h4 class="title">Types of reviews</h4> <p>For this overview of reviews, we included all published Cochrane systematic reviews of randomised controlled trials (RCTs) that examined: </p> <p> <ul id="CD012103-list-0002"> <li> <p>interventions that aimed to prevent OHSS with reporting on the incidence of moderate, severe or overall OHSS as a primary outcome; and </p> </li> <li> <p>other interventions in ART cycles with reporting on the incidence of moderate, severe or overall OHSS as a secondary outcome. </p> </li> </ul> </p> <p>Moreover, we listed the protocols of reviews and title registrations on OHSS prevention in a table included in the overview. Thus we will be able to identify and add new reviews, once published, at the time of the next overview update. We excluded reviews on non‐ART cycles and reviews on ART cycles that did not report on OHSS as an outcome. </p> </section> <section id="CD012103-sec-0024"> <h4 class="title">Types of participants</h4> <p>We included reviews that enrolled women who underwent fresh ART cycles, including those who acted as oocyte donors. We considered Cochrane systematic reviews that reported on ‘high risk’ subgroups (e.g. minimum number of follicles, minimum number of oocytes retrieved, minimum oestradiol level, women with PCOS) and those that reported on unselected populations. We excluded reviews of non‐ART cycles, such as ovulation induction or intrauterine insemination cycles. </p> </section> <section id="CD012103-sec-0025"> <h4 class="title">Types of interventions</h4> <p>We considered for inclusion reviews on two types of interventions.</p> <p> <ul id="CD012103-list-0003"> <li> <p>Interventions specifically aimed at prevention of OHSS for which OHSS was reported as a primary outcome. </p> </li> <li> <p>Any interventions in ART cycles for which OHSS was reported as a secondary outcome.</p> </li> </ul> </p> </section> </section> <section id="CD012103-sec-0026"> <h3 class="title">Search methods for identification of reviews</h3> <p>We searched for reviews within the <i>Cochrane Database of Systematic Reviews</i> and Archie (the Cochrane information management system) for the following keywords: in vitro fertilisation (IVF), intracytoplasmic sperm injection (ICSI), ART, adverse events and OHSS (search dates 18/11/2015, 24/7/2016 and 12/12/2016). The overview 'Assisted reproductive technology: an overview of Cochrane Reviews' by <a href="./references#CD012103-bbs2-0072" title="FarquharC , RishworthJR , BrownJ , NelenWLDM , MarjoribanksJ . Assisted reproductive technology: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD010537.pub4] ">Farquhar 2015</a> identified all current reviews on ART that reported on OHSS as a primary or secondary outcome, and we used this as complementary guidance. </p> </section> <section id="CD012103-sec-0027"> <h3 class="title" id="CD012103-sec-0027">Data collection and analysis</h3> <p>We based the methods used for data collection and analysis for this overview on Chapter 22 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012103-bbs2-0066" title="BeckerLA , OxmanAD . Chapter 22: Overviews of reviews. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Becker 2011</a>; <a href="./references#CD012103-bbs2-0077" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration,2011. www.cochrane‐handbook.org. ">Higgins 2011</a><i>).</i> </p> <section id="CD012103-sec-0028"> <h4 class="title">Primary outcomes</h4> <p>The primary outcome measure is the incidence of moderate, severe and overall OHSS per woman randomised. </p> <p>The OHSS subgroups of moderate and severe are defined by the criteria set forth by <a href="./references#CD012103-bbs2-0061" title="AboulgharMA , MansourRT . Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Human Reproduction Update2003;9(3):275‐89. ">Aboulghar 2003</a>, <a href="./references#CD012103-bbs2-0073" title="GolanA , Ron‐ElR , HermanA , SofferY , WainraubZ , CaspiE . Ovarian hyperstimulation syndrome: an update review. Obstetrical and Gynecological Survey1989;44(6):430‐40. ">Golan 1989</a>, <a href="./references#CD012103-bbs2-0085" title="NavotD , BerghPA , LauferN . Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility1992;58(2):249‐61. ">Navot 1992</a>, <a href="./references#CD012103-bbs2-0086" title="RabauE , SerrDM , DavidA , MaschiacS , LunenfieldB . Human menopausal gonadotropins for anovulation and sterility. American Journal of Obstetrics and Gynaecology1967;98:92‐8. ">Rabau 1967</a>, <a href="./references#CD012103-bbs2-0087" title="RizkB , AboulgharMA . Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: BrinsdenP editor(s). In‐Vitro Fertilization and Assisted Reproduction. New York, London: The Parthenon Publishing Group, 1999:131‐55. ">Rizk 1999</a> and <a href="./references#CD012103-bbs2-0088" title="SchenkerJG , WeinsteinD . Ovarian hyperstimulation syndrome: a current survey. Fertility and Sterility1978;30(3):255‐68. ">Schenker 1978</a>, or by any other classification used in the included reviews (<a href="./appendices#CD012103-sec-0082">Appendix 1</a>). </p> </section> <section id="CD012103-sec-0029"> <h4 class="title">Secondary outcomes</h4> <p>Secondary outcomes studied were live birth rate, clinical pregnancy rate, miscarriage rate, multiple pregnancy rate and any reported adverse effects that derived from the interventions studied (as reported by separate reviews, e.g. side effects of medication, admission to the hospital). </p> </section> <section id="CD012103-sec-0030"> <h4 class="title">Selection of reviews</h4> <p>Two overview authors independently selected reviews for inclusion according to the criteria stated. A third overview author acted as a referee and discussed disagreements that arose. We added the following to the overview for future overview updates: protocols of reviews and title registrations on prevention of OHSS submitted to the Cochrane Library, and reviews on ART interventions that will report on OHSS as a secondary outcome. </p> </section> <section id="CD012103-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>Two overview authors (SM and JB) performed data extraction using a Microsoft Excel spreadsheet. If data from the reviews were unclear or seemed to be missing, we contacted review authors for clarification, searched primary RCTs or contacted primary study authors for details. A third overview author (CF) acted as a referee and discussed discrepancies or disputes that arose. </p> <p>We extracted and summarised the following data for the additional tables.</p> <p> <ul id="CD012103-list-0004"> <li> <p>Population demographics: participant characteristics, definition of high‐risk groups when applicable. </p> </li> <li> <p>Review characteristics: number of included trials, number of participants, date the review was assessed as up‐to‐date (date of search), interventions and comparisons, all primary and secondary outcomes and limitations of the review. </p> </li> <li> <p>Timing of intervention: e.g. pretreatment selection of participants, pretreatment adjuvant therapy, stimulation phase, stimulation phase adjuvant treatment, ovulation trigger, embryo transfer phase, luteal support phase. </p> </li> <li> <p>Statistical summary: summary effects from relevant comparisons on our primary outcome of moderate, severe or overall OHSS. </p> </li> </ul> </p> <p>We used the same summary effect measures as were used in the original reviews, in most cases odds ratios. </p> </section> <section id="CD012103-sec-0032"> <h4 class="title">Assessment of methodological quality of included reviews</h4> <p>Two overview authors independently assessed the quality of the evidence derived from included systematic reviews. We resolved discrepancies by discussion, and a third overview author acted as an arbiter. </p> <section id="CD012103-sec-0033"> <h5 class="title">Quality of evidence from primary studies in included reviews</h5> <p>Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method, we summarised the quality of the evidence from primary studies in the included reviews (<a href="./references#CD012103-bbs2-0076" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchünemannHJ , GRADE Working Group. Rating quality of evidence and strength of recommendations: what is "quality of evidence" and why is it important to clinicians?. BMJ2008;336(7651):995‐8. '>Guyatt 2008</a>; <a href="./references#CD012103-bbs2-0090" title="SchünemannH , BrozekJ , GuyattG , OxmanA (editors) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated March 2013. http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html (accessed 15 November 2015). ">Schünemann 2013</a>). We prepared 'Summary of findings' tables using GRADEpro Guideline Development Tool (GDT) software (<a href="./references#CD012103-bbs2-0074" title="GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime Inc.). www.gradepro.org. ">GRADEpro GDT</a>) for overview outcomes for each comparison by taking ratings from the original review, or we appraised the review ourselves if the review had not yet been assessed through the GRADE approach. </p> <p> <ul id="CD012103-list-0005"> <li> <p>Risk of bias of included trials.</p> </li> <li> <p>Directness of the evidence.</p> </li> <li> <p>Precision of the evidence.</p> </li> <li> <p>Heterogeneity.</p> </li> <li> <p>Risk of publication bias.</p> </li> </ul> </p> <p>We summarised the evidence for each of the selected clinical outcomes in a 'Summary of findings' table, to which we added the summary risk estimate and 95% confidence intervals. We allocated the quality of evidence for the clinical outcome with a score for strength of the evidence, ranging from 'high' to 'very low'. </p> </section> <section id="CD012103-sec-0034"> <h5 class="title">Quality of included reviews</h5> <p>We assessed the methodological quality of included reviews using the AMSTAR (Assessing the Methodological Quality of Systematic Reviews) instrument (<a href="./references#CD012103-bbs2-0091" title="SheaBJ , GrimshawJM , WellsGA , BoersM , AnderssonN , HamelC , et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology2007;7:10. ">Shea 2007</a>). This instrument evaluates methods used in systematic reviews and the degree to which reviews are biased by comparing them on the basis of distinct criteria. Ratings used in AMSTAR include 'yes' (clearly done), 'no' (clearly not done), 'cannot answer' and 'not applicable' (<a href="./appendices#CD012103-sec-0084">Appendix 2</a>). </p> </section> </section> <section id="CD012103-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We undertook a narrative description of the included trials. We included an ‘Overview of reviews’ table, which shows the characteristics of included reviews. Moreover, we displayed a summary of the quality of evidence within individual reviews that was based on GRADE judgements, and we provided an AMSTAR rating for each included review. </p> <p>We summarised the main results of the included systematic reviews and the effect on OHSS rates of their individual comparisons using the following framework. </p> <p> <ul id="CD012103-list-0006"> <li> <p>Effective interventions: indicates that the review found evidence of effectiveness for an intervention. </p> </li> <li> <p>Promising interventions (more evidence needed): indicates that the review found some evidence of effectiveness for an intervention, but more evidence is needed. </p> </li> <li> <p>Ineffective interventions: indicates that the review found evidence of lack of effectiveness for an intervention. </p> </li> <li> <p>Probably ineffective interventions (more evidence needed): indicates that the review found evidence suggesting lack of effectiveness for an intervention, but more evidence is needed. </p> </li> <li> <p>No conclusions possible due to lack of evidence: indicates that the review found insufficient evidence for review authors to comment on the effectiveness of an intervention. </p> </li> </ul> </p> <p>The choice of category to be allocated reflects the conclusions stated by authors of the individual reviews and our judgement as overview authors. We resolved disagreements by discussion. </p> <p>We based our approach to summarising the evidence on the framework used for the ART overview (<a href="./references#CD012103-bbs2-0072" title="FarquharC , RishworthJR , BrownJ , NelenWLDM , MarjoribanksJ . Assisted reproductive technology: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD010537.pub4] ">Farquhar 2015</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012103-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012103-sec-0036"></div> <p>Upon screening the ART overview (<a href="./references#CD012103-bbs2-0072" title="FarquharC , RishworthJR , BrownJ , NelenWLDM , MarjoribanksJ . Assisted reproductive technology: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD010537.pub4] ">Farquhar 2015</a>), we identified a total of 20 reviews reporting on OHSS as an outcome. We subsequently screened full texts for remaining reviews in the ART overview reporting on OHSS or adverse events that could include OHSS as an outcome. By doing this, we identified an additional seven reviews (see flow diagram of included reviews, <a href="./full#CD012103-fig-0001">Figure 1</a>). We excluded 33 reviews from the ART overview for not reporting on OHSS. From the Cochrane Gynaecology and Fertility (CGF) Database of registered titles, we identified no titles that were expected to report on OHSS in ART cycles as an outcome. From the CGF database of submitted protocols, we identified four protocols that potentially would report on OHSS in ART cycles as an outcome (<a href="./appendices#CD012103-sec-0086">Appendix 3</a>). Most often, we excluded titles and protocols because they did not concern ART cycles or because they concerned laboratory interventions. </p> <div class="figure" id="CD012103-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of included reviews." data-id="CD012103-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012103.pub2/media/CDSR/CD012103/image_n/nCD012103-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of included reviews.</p> </div> </div> </div> <section id="CD012103-sec-0037"> <h3 class="title" id="CD012103-sec-0037">Description of included reviews</h3> <p>In total, we included 27 Cochrane systematic reviews that reported on OHSS (85,497 participants). See <a href="#CD012103-tbl-0001">Table 1</a> for a summary of the characteristics of these reviews (review title and author, numbers of randomised controlled trials and participants included, interventions and comparisons, outcomes, main limitations of each review). Of the 27 included reviews, two were empty reviews (reviews with no included studies), with last search dates in 2009 and 2011, respectively (<a href="./references#CD012103-bbs2-0016" title="SiristatidisCS , MaheshwariA , BhattacharyaS . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006606.pub2] ">Siristatidis 2009</a>; <a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a>). We deemed two reviews to be stable, meaning that searches would be repeated only when review authors became aware of newly published evidence (<a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a>; <a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a>). </p> <div class="table" id="CD012103-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Review characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of included trials</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> <p><b><i>Definition of high risk for OHSS (where applicable)</i> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison intervention/control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review limitations</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA563</p> <p><a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a> </p> <p>Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>340 women with PCOS</p> <p>downregulated by GnRHa, undergoing superovulation in IVF or ICSI cycles</p> <p><i>High risk: women with PCOS</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coasting when</p> <p>oestradiol levels were &gt; 2500 pg/mL or &gt; 9000 pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Early unilateral follicular</p> <p>aspiration</p> <p>No coasting or other interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Number of oocytes retrieved</p> <p>Multiple pregnancy</p> <p>Miscarriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparisons based on limited trial data</p> <p>Live birth reported in only 1 trial</p> <p>Trials lacked blinding, and half the trials lacked details on allocation concealment and incomplete outcome assessment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA561</p> <p><a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a> </p> <p>Embryo freezing for preventing ovarian hyperstimulation syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151 women</p> <p>downregulated by GnRHa, undergoing superovulation in IVF or ICSI cycles.</p> <p><i>High risk: as defined by included studies</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cryopreservation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fresh embryo transfer</p> <p>Intravenous albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Clinical pregnancy<sup>a</sup> </p> <p>Live birth</p> <p>Admissions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence based on 2 trials, 1 for each comparison</p> <p>Live birth reported in only 1 trial</p> <p>Issues around methodological quality of both trials</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TH1338</p> <p><a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a> </p> <p>Dopamine agonists for preventing ovarian hyperstimulation syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2091 women at high risk of developing OHSS undergoing ART</p> <p><i>High risk: as defined by included studies</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cabergoline quinagolide, bromocriptine,</p> <p>cabergoline + albumin,</p> <p>cabergoline + HES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo/no treatment/other treatment:</p> <p>Albumin alone</p> <p>HES</p> <p>Coasting</p> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Adverse effects</p> <p>Miscarriage</p> <p>Multiple pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation concealment and blinding not adequately reported.</p> <p>One study used a co‐intervention of albumin IV and 1 of HES</p> <p>Different regimens of cabergoline administration between included studies</p> <p>Live birth rate reported in only 2 studies</p> <p>Incomplete reporting of multiple pregnancy rate, adverse effects and miscarriage rate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMA481</p> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> <p>Volume expanders for prevention of OHSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1660 (albumin) + 487 (HES) women</p> <p>at high risk of developing OHSS undergoing ART cycles <i>High risk: determined as number of follicles or oestradiol levels on day of hCG, as defined by included studies</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Human albumin</p> <p>Hydroxyethyl starch (HES)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Number of oocytes retrieved</p> <p>Multiple pregnancy</p> <p>Miscarriage</p> <p>Live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No reporting of live birth rate</p> <p>Limited by incomplete data reporting and lack of (details on) blinding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA413</p> <p><a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a> </p> <p>Recombinant vs urinary hCG for final oocyte maturation triggering in IVF and ICSI cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2952 women undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant hCG</p> <p>Recombinant LH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Miscarriage</p> <p>Oocytes retrieved</p> <p>Tolerance</p> <p>Live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Review authors combined ongoing pregnancy and live births together</p> <p>Only 7 trials reported on live birth</p> <p>Trials lacked details on allocation concealment, randomisation and blinding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MM1690</p> <p><a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a> </p> <p>GnRHa vs hCG for oocyte triggering in antagonist‐assisted reproductive technology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1847 women undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GnRH agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth rate<sup>a</sup> </p> <p>Ongoing pregnancy</p> <p>Clinical pregnancy</p> <p>Multiple pregnancy</p> <p>Miscarriage rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias in included studies. Limitations included premature termination, failure to clearly report methods and substantial heterogeneity </p> <p>Adverse events such as multiple pregnancy rate were not well reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AWP1710</p> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> <p>Long‐acting FSH vs daily FSH for women undergoing assisted reproduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3753 women with subfertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daily FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth rate<sup>a</sup> </p> <p>Ongoing pregnancy rate</p> <p>Clinical pregnancy rate</p> <p>Multiple pregnancy rate</p> <p>Miscarriage rate</p> <p>Adverse events</p> <p>Satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited by risk of attrition bias in some primary studies and by serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LDT120</p> <p><a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a> </p> <p>Metformin treatment before and during IVF or ICSI in women with PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>816 women with PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy<sup>a</sup> Miscarriage </p> <p>Adverse events Number of oocytes</p> <p>retrieved</p> <p>Total dose FSH (IU) Number of days</p> <p>gonadotrophin treatment</p> <p>Cycle cancellation rate</p> <p>Serum E2 level (nmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Half the trials were not blinded and lacked details on allocation concealment and randomisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM1335</p> <p><a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a> </p> <p>Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing IVF </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 RCTs,</p> <p>12 for meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2536 (12 trials)</p> <p>Subfertile women undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate</p> <p>± additional treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alternative treatments for</p> <p>COH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth rate<sup>a</sup> </p> <p>Miscarriage rate</p> <p>Ectopic pregnancy</p> <p>Foetal abnormality</p> <p>Ongoing pregnancy rate</p> <p>Cancellation rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth reported in only 5 trials</p> <p>Most studies suffered from suboptimal methods and information on some outcomes was insufficient </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TA1860</p> <p><a href="./references#CD012103-bbs2-0003" title="AllersmaT , FarquharC , CantineauAEP . Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010550.pub2] ">Allersma 2013</a> </p> <p>Natural cycle IVF for subfertile couples</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>382 subfertile women and couples undertaking IVF treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Natural cycle IVF</p> <p>Modified natural cycle IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COH IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Pregnancy</p> <p>Ongoing pregnancy</p> <p>Number of oocytes retrieved</p> <p>Time to live birth</p> <p>Number of cycles required to conceive</p> <p>Cumulative pregnancy/live birth rate</p> <p>Multiple pregnancy</p> <p>Lack of embryos for cryopreservation</p> <p>Cycle cancellation</p> <p>Gestational abnormalities</p> <p>Cancellation of treatment</p> <p>Cost‐effectiveness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Few studies, live birth reported in only 1 very small trial</p> <p>Inclusion criteria differed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MV263</p> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> <p>Luteal phase support for ART cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26,198 women with any cause of subfertility undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progesterone</p> <p>hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo or no treatment</p> <p>hCG</p> <p>Progesterone + oestrogen Progesterone + GnRHa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Ongoing pregnancy</p> <p>Miscarriage</p> <p>OHSS</p> <p>Multiple pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor reporting of study methods and imprecision due to small sample sizes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA412</p> <p><a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a> </p> <p>Gonadotrophin‐releasing hormone antagonists for ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,212 women undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GnRH antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐course GnRHa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Ongoing pregnancy</p> <p>Clinical pregnancy</p> <p>Miscarriage</p> <p>Cycle cancellation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 12 trials reported live birth</p> <p>Trial methods limited by lack of blinding</p> <p>Poor reporting of study methods for OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMY731</p> <p><a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a> </p> <p>IVF vs tubal re‐anastomosis (sterilisation reversal) for subfertility after tubal sterilisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tubal re‐anastomosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy Multiple pregnancy</p> <p>Other serious maternal morbidity, (incl OHSS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Empty review with no</p> <p>trials</p> <p>No longer being updated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ZP672</p> <p><a href="./references#CD012103-bbs2-0013" title="PandianZ , GibreelA , BhattacharyaS . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003357.pub3] ">Pandian 2015</a> </p> <p>IVF for unexplained subfertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>733 couples with unexplained subfertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Expectant management</p> <p>Intrauterine insemination Intrauterine insemination +</p> <p>ovarian stimulation</p> <p>Clomiphene citrate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy Multiple pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some evidence was based</p> <p>on a single trial</p> <p>Limitations included imprecision and heterogeneity for some outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LA541</p> <p><a href="./references#CD012103-bbs2-0002" title="AlbuquerqueLET , TsoLO , SaconatoH , AlbuquerqueMCRM , MacedoCR . Depot versus daily administration of gonadotrophin‐releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002808.pub3] ">Albuquerque 2013</a> </p> <p>Depot vs daily administration of GnRHa protocols for pituitary desensitisation in assisted reproduction cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 RCTs,</p> <p>12 for meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1811 couples with any cause of subfertility undergoing IVF with COH with hFSH, hMG or rFSH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pituitary downregulation with depot administration of GnRHa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daily administration of GnRHa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy<sup>a</sup> </p> <p>Miscarriage</p> <p>Multiple pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S tudy quality unclear due to poor reporting. O nly four stu dies reported live birth an d only five described adequate methods for allocation concealment . </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK973</p> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> <p>Recombinant vs urinary gonadotrophin for ovarian stimulation in ART cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9606 normogonadotrophic women undergoing fresh and/or frozen thawed IVF or ICSI cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference reported in moderate/severe OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WPM1780</p> <p><a href="./references#CD012103-bbs2-0011" title="MartinsWP , VieiraADD , FigueiredoJBP , NastriCO . FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010042.pub2] ">Martins 2013</a> </p> <p>FSH replaced by low‐dose hCG in the late follicular phase vs continued FSH for ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>351 women undergoing COH for ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low‐dose hCG instead of FSH in late follicular phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continued FSH in late follicular phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Miscarriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small studies and low event rate</p> <p>Total OHSS incidence reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHH752</p> <p><a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a> </p> <p>Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing ART </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2596 women of any age with subfertility regardless of cause, undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pretreatment with combined oral contraceptive pills</p> <p>Pretreatment with progestogens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No pretreatment</p> <p>Placebo</p> <p>Progestogens</p> <p>Oestrogens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy</p> <p>Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 3/23 studies reported on OHSS</p> <p>2 of these 3 studies did not define how they diagnosed the condition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK972</p> <p><a href="./references#CD012103-bbs2-0010" title="KwanI , BhattacharyaS , KangA , WoolnerA . Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005289.pub3] ">Kwan 2014</a> </p> <p>Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>781 women undergoing COH in an IVF/ICSI cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transvaginal ultrasonography + Oestradiol measurement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transvaginal ultrasonography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy</p> <p>Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only total OHSS reported, including mild OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMB1261</p> <p><a href="./references#CD012103-bbs2-0004" title="BoomsmaCM , KeaySD , MacklonNS . Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005996.pub3] ">Boomsma 2012</a> </p> <p>Peri‐implantation glucocorticoid administration for ART cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1879 subfertile patients undergoing IVF/ICSI, regardless of cause of infertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucocorticoids in the peri‐implantation phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No glucocorticoids in the peri‐implantation phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>Multiple pregnancy<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy Miscarriage</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 2 studies, pooled total OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VJP951</p> <p><a href="./references#CD012103-bbs2-0018" title="SiristatidisCS , BasiosG , PergialiotisV , VogiatziP . Aspirin for in vitro fertilisation. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD004832.pub4] ">Siristatidis 2016</a> </p> <p>Aspirin for IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2653 women undergoing IVF/ICSI and their partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aspirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 1 of 13 studies reported on OHSS and without exact numbers or explanation for numerators/denominators </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CS1400</p> <p><a href="./references#CD012103-bbs2-0016" title="SiristatidisCS , MaheshwariA , BhattacharyaS . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006606.pub2] ">Siristatidis 2009</a> </p> <p>In vitro maturation in subfertile women with PCOS undergoing assisted reproduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 women with PCOS and subfertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro maturation + IVF/ICSI in women with PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional IVF/ICSI in women with PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Effectiveness</p> <p>Clinical pregnancy Miscarriage</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Empty review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRS911</p> <p><a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a> </p> <p>Acupuncture and ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4544 women undergoing ART, any type of acupuncture at any time point before, after or during ART, intended to improve ART outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acupuncture of men, women or both during COH</p> <p>Acupuncture + ART</p> <p>Acupuncture alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment</p> <p>Placebo</p> <p>Sham acupuncture</p> <p>Acupuncture + ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No trials reported on OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MHM931</p> <p><a href="./references#CD012103-bbs2-0012" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a> </p> <p>Recombinant luteinising hormone (rLH) for COH in assisted reproductive cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2612 subfertile ovulatory women undergoing IVF or ICSI</p> <p>High risk: NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Combination of rLH and rFSH for COH in IVF/ICSI followed by ET in GnRHa and GnRH antagonist protocols </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rFSH alone for COH in IVF/ICSI followed by ET in GnRHa and GnRH antagonist protocols</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy Miscarriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 4/14 trials reported on OHSS</p> <p>Pooled OHSS</p> <p>No GRADE assessment in old version</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KH291</p> <p><a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a> </p> <p>Growth hormone for IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>440 women part of a subfertile couple undergoing IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant growth hormone during conventional IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 4 of 10 RCTs reported on adverse events (which could include OHSS)</p> <p>1 study actually mentioned OHSS (however, no cases); pooled OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD265</p> <p><a href="./references#CD012103-bbs2-0017" title="Siristatidis CharalamposS , GibreelA , BasiosG , MaheshwariA , BhattacharyaS . Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2015, issue 11. [DOI: 10.1002/14651858.CD006919.pub4; CD006919] ">Siristatidis 2015</a> </p> <p>GnRHa protocols for pituitary suppression in assisted reproduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3872 women/couples with all types of infertility undergoing ART and using GnRHa for pituitary downregulation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long protocol</p> <p>Long luteal protocol</p> <p>Short protocol</p> <p>Dose continued</p> <p>Dose continued after hCG administration</p> <p>Pretreatment 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short protocol</p> <p>Ultrashort protocol</p> <p>Long follicular phase protocol</p> <p>Ultrashort protocol</p> <p>Dose stopped</p> <p>Dose reduced</p> <p>Dose discontinued after hCG administration</p> <p>Pretreatment 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 2 of 37 included RCTs reported on OHSS for 2 of 9 compared regimens</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>JC1630</p> <p><a href="./references#CD012103-bbs2-0015" title="ShowellMG , BrownJ , ClarkeJ , HartRJ . Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD007807.pub2] ">Showell 2013</a> </p> <p>Antioxidants for female subfertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3548 subfertile women referred to fertility clinic who might or might not undergo ART (IVF, ICSI or IUI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant antioxidants in females</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment</p> <p>Placebo</p> <p>Another antioxidant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects (incl OHSS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 3 studies reported: 1 no data and 2 no cases</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Primary review outcome. </p> <p>ART: artifical reproductive technology.</p> <p>COH: controlled ovarian hyperstimulation.</p> <p>ET: embryo transfer.</p> <p>FSH: follicle‐stimulating hormone.</p> <p>GnRHa: gonadotrophin‐releasing hormone agonist.</p> <p>hCG: human chorionic gonadotrophin.</p> <p>HES: hydroxyethyl starch.</p> <p>hFSH: human follicle‐stimulating hormone.</p> <p>hMG: human menopausal gonadotrophin.</p> <p>ICSI: intracytoplasmic sperm injection.</p> <p>IUI: intrauterine insemination.</p> <p>IVF: in vitro fertilisation.</p> <p>LH: luteinising hormone.</p> <p>NA: not applicable.</p> <p>OHSS: ovarian hyperstimulation syndrome.</p> <p>PCOS: polycystic ovary syndrome.</p> <p>RCT: randomised controlled trial.</p> <p>rFSH: recombinant follicle‐stimulating hormone.</p> <p>rLH: recombinant luteinising hormone.</p> </div> </div> <p><a href="./references#CD012103-bbs2-0013" title="PandianZ , GibreelA , BhattacharyaS . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003357.pub3] ">Pandian 2015</a> (IVF for unexplained subfertility) compared IVF versus IUI (we did not formally consider IUI a treatment for inclusion in this overview). As all studies also included a IVF/ICSI comparator group, we decided that we should include this review in the overview. Also, <a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a> ('Acupuncture and assisted reproductive technology') could theoretically include studies on IUI or ovulation induction; however, all current comparisons in this review involve acupuncture around the time of oocyte retrieval and/or embryo transfer, which means that the current version of the review reports only on IVF/ICSI treatments. </p> <section id="CD012103-sec-0038"> <h4 class="title">Reporting on OHSS</h4> <p>A total of 15 reviews reported on OHSS as a primary outcome, and 12 reported on OHSS as a secondary outcome. The number of included primary studies per review ranged from zero to 94. We also noted large variation in the number of included primary studies that <i>actually</i> reported data on OHSS, which ranged from zero to 32 studies. For example, in the review that included 94 primary studies, only one study actually reported on OHSS (<a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a>). </p> <p>Four reviews focused specifically on prevention of OHSS and compared the following interventions: coasting versus no/other treatment (<a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a>), embryo freezing versus fresh transfer or intravenous albumin plus fresh transfer (<a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a>), volume expanders versus placebo or no treatment (<a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a>) and dopamine agonists versus placebo or no/other treatment (<a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a>). These reviews included studies that identified high‐risk groups on the basis of oestradiol levels, a minimum number of follicles of a certain size, a minimum number of retrieved oocytes or a diagnosis of PCOS. Some primary studies excluded extremely high risk groups on the basis of oestradiol levels. </p> <p>Three reviews (<a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a>; <a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a>; <a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a>) reported separately on the subgroups 'moderate' and 'severe' OHSS, and two reported only on 'severe OHSS' (<a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a>; <a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a>). The other 22 reviews were described as reporting 'total OHSS' with or without defining this as inclusion of mild, moderate or severe cases. </p> </section> <section id="CD012103-sec-0039"> <h4 class="title">Timing of intervention</h4> <p>Timing of interventions in the included reviews differed (see <a href="#CD012103-tbl-0001">Table 1</a>) as follows. </p> <p> <ul id="CD012103-list-0007"> <li> <p>No reviews: interventions regarding pretreatment selection of participants.</p> </li> <li> <p>Five reviews: interventions regarding pretreatment adjuvant therapy (<a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a>; <a href="./references#CD012103-bbs2-0015" title="ShowellMG , BrownJ , ClarkeJ , HartRJ . Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD007807.pub2] ">Showell 2013</a>; <a href="./references#CD012103-bbs2-0016" title="SiristatidisCS , MaheshwariA , BhattacharyaS . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006606.pub2] ">Siristatidis 2009</a>; <a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a>; <a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a>). </p> </li> <li> <p>One review: the pituitary downregulation phase (<a href="./references#CD012103-bbs2-0002" title="AlbuquerqueLET , TsoLO , SaconatoH , AlbuquerqueMCRM , MacedoCR . Depot versus daily administration of gonadotrophin‐releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002808.pub3] ">Albuquerque 2013</a>). </p> </li> <li> <p>No reviews: interventions regarding adjuvants during the stimulation phase.</p> </li> <li> <p>11 reviews: interventions regarding the stimulation phase (<a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a>; <a href="./references#CD012103-bbs2-0003" title="AllersmaT , FarquharC , CantineauAEP . Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010550.pub2] ">Allersma 2013</a>; <a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a>; <a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a>; <a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a>; <a href="./references#CD012103-bbs2-0010" title="KwanI , BhattacharyaS , KangA , WoolnerA . Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005289.pub3] ">Kwan 2014</a>; <a href="./references#CD012103-bbs2-0011" title="MartinsWP , VieiraADD , FigueiredoJBP , NastriCO . FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010042.pub2] ">Martins 2013</a>; <a href="./references#CD012103-bbs2-0012" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a>; <a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a>; <a href="./references#CD012103-bbs2-0017" title="Siristatidis CharalamposS , GibreelA , BasiosG , MaheshwariA , BhattacharyaS . Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2015, issue 11. [DOI: 10.1002/14651858.CD006919.pub4; CD006919] ">Siristatidis 2015</a>; <a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a>). </p> </li> <li> <p>Three reviews: the ovulation trigger phase (<a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a>; <a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a>; <a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a>). </p> </li> <li> <p>Three reviews: the embryo transfer phase (<a href="./references#CD012103-bbs2-0004" title="BoomsmaCM , KeaySD , MacklonNS . Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005996.pub3] ">Boomsma 2012</a>; <a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a>; <a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a>). </p> </li> <li> <p>One review: the luteal support phase (<a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a>). </p> </li> </ul> </p> <p>We could not classify the <a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a> and <a href="./references#CD012103-bbs2-0013" title="PandianZ , GibreelA , BhattacharyaS . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003357.pub3] ">Pandian 2015</a> reviews according to this framework because they studied IVF versus other strategies. </p> </section> <section id="CD012103-sec-0040"> <h4 class="title">Main limitations of the reviews</h4> <p>The major and most frequent limitations of included reviews were the mere reporting of 'total OHSS', as opposed to reporting separately on the more clinically relevant subgroups 'moderate' and 'severe'; failure to include any or inclusion of only a few studies per comparison; and a generally low proportion of primary studies reporting data on OHSS. </p> <p>The 12 reviews that did report on OHSS as a secondary outcome often described lack of statistical power for the outcome 'OHSS' due to the low incidence of the condition in general and more specifically in populations not selected for risk of developing OHSS. For example, given a population size of 2000 women undergoing ART, as well as a 5% margin of error and a 95% confidence interval, the required sample size would be 323 women. In light of the fact that the incidence of moderate to severe OHSS in this population would be set at 5% (range from literature 3% to 8%), at least 6460 women should be included in the study for enough women to develop OHSS that data would show differences in OHSS rates. For most countries and settings, this inclusion number is not realistically attainable for any study. </p> </section> <section id="CD012103-sec-0041"> <h4 class="title">Last search date of the reviews</h4> <p><a href="#CD012103-tbl-0002">Table 2</a> shows the last search date per review. Only 17 of the 27 included reviews conducted a literature search within the past three years (to 12 December 2016), and overview authors deemed an additional two reviews (<a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a>; <a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a>) with an older literature search to be stable. At our third search date (12 December 2016), we became aware of four reviews that were in the process of being updated (<a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a>; <a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a>; <a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a>; <a href="./references#CD012103-bbs2-0012" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a>). Progress of these updates at the date of the search varied widely, from just starting the literature search to completing the final editorial phase. </p> <div class="table" id="CD012103-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Last search date assessment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Review no.</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>First review author</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review title</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Date last assessed <br/> up to date</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&lt; 3 years since last assessed up to date or deemed stable</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embryo freezing for preventing OHSS</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/11/2010</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stable</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA 563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coasting (withholding of gonadotrophins) for preventing OHSS</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/07/2010</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TH1338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dopamine agonists for preventing OHSS</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/08/2016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMA481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume expanders for prevention of OHSS</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/09/2016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant vs urinary hCG for final oocyte maturation triggering in IVF and ICSI cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/04/2015</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MM1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GnRHa vs hCG for oocyte triggering in antagonist‐assisted reproductive technology</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>08/09/2014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LDT1201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metformin treatment before and during IVF or ICSI in women with PCOS</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/10/2014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AWP1710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH vs daily FSH for women undergoing assisted reproduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/06/2015</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate in combination with gonadotrophins for controlled ovarian stimulation in women undergoing IVF </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/03/2012</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TA1860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0003" title="AllersmaT , FarquharC , CantineauAEP . Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010550.pub2] ">Allersma 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Natural cycle IVF for subfertile couples</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/03/2013</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MV263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden</a><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/11/2014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotrophin‐releasing hormone antagonists for ART</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/04/2016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMY731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IVF vs tubal re‐anastomosis (sterilisation reversal) for subfertility after tubal sterilisation </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/05/2009</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Empty, stable</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ZP672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0013" title="PandianZ , GibreelA , BhattacharyaS . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003357.pub3] ">Pandian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IVF for unexplained subfertility</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/05/2015</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LA541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0002" title="AlbuquerqueLET , TsoLO , SaconatoH , AlbuquerqueMCRM , MacedoCR . Depot versus daily administration of gonadotrophin‐releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002808.pub3] ">Albuquerque 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depot vs daily administration of GnRHa protocols for pituitary desensitisation in assisted reproduction<br/> cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/07/2012</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant vs urinary gonadotrophin for ovarian stimulation in ART cycles</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/10/2010</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WPM1780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0011" title="MartinsWP , VieiraADD , FigueiredoJBP , NastriCO . FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010042.pub2] ">Martins 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH replaced by low‐dose hCG in late follicular phase vs continued FSH for ART</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/02/2013</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHH752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing ART </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/11/2008</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0010" title="KwanI , BhattacharyaS , KangA , WoolnerA . Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005289.pub3] ">Kwan 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/05/2014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMB1261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0004" title="BoomsmaCM , KeaySD , MacklonNS . Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005996.pub3] ">Boomsma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peri‐implantation glucocorticoid administration for ART cycles</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/09/2011</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VJP951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0018" title="SiristatidisCS , BasiosG , PergialiotisV , VogiatziP . Aspirin for in vitro fertilisation. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD004832.pub4] ">Siristatidis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aspirin for IVF</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/05/2016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CS1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0016" title="SiristatidisCS , MaheshwariA , BhattacharyaS . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006606.pub2] ">Siristatidis 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro maturation in subfertile women with PCOS undergoing assisted reproduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/02/2011</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Empty</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRS911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acupuncture and ART</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/07/2013</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MHM931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0012" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant luteinising hormone (rLH) for COH in assisted reproductive cycles</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/01/2007</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KH291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Growth hormone for IVF</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/07/2009</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0017" title="Siristatidis CharalamposS , GibreelA , BasiosG , MaheshwariA , BhattacharyaS . Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2015, issue 11. [DOI: 10.1002/14651858.CD006919.pub4; CD006919] ">Siristatidis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GnRHa protocols for pituitary suppression in assisted reproduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/04/2015</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>JC1630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0015" title="ShowellMG , BrownJ , ClarkeJ , HartRJ . Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD007807.pub2] ">Showell 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antioxidants for female subfertility</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/04/2014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ART: artifical reproductive technology.</p> <p>COH: controlled ovarian hyperstimulation.</p> <p>FSH: follicle‐stimulating hormone.</p> <p>GnRHa: gonadotrophin‐releasing hormone agonist.</p> <p>hCG: human chorionic gonadotrophin.</p> <p>ICSI: intracytoplasmic sperm injection.</p> <p>IUI: intrauterine insemination.</p> <p>IVF: in vitro fertilisation.</p> <p>OHSS: ovarian hyperstimulation syndrome.</p> <p>PCOS: polycystic ovary syndrome.</p> <p>rLH: recombinant luteinising hormone.</p> <p>✔ under 3 years since last assessed as up to date</p> <p><b>X</b> over 3 years since last assessed as up to date </p> </div> </div> </section> <section id="CD012103-sec-0042"> <h4 class="title">Statistical summary</h4> <section id="CD012103-sec-0043"> <h5 class="title">Quality of evidence from primary studies in included reviews</h5> <p>The quality of the evidence reported by primary studies in the included reviews assessed by the GRADE approach ranged from very low to high for individual comparisons. The main reasons for downgrading of reviews for quality included inadequate reporting of allocation concealment and randomisation methods, lack of blinding and imprecision. Eleven of the 27 reviews included fewer than 10 primary studies. </p> </section> </section> </section> <section id="CD012103-sec-0044"> <h3 class="title" id="CD012103-sec-0044">Methodological quality of included reviews</h3> <section id="CD012103-sec-0045"> <h4 class="title">Quality of systematic reviews</h4> <p>We rated the quality of the included reviews using the AMSTAR tool (<a href="./references#CD012103-bbs2-0091" title="SheaBJ , GrimshawJM , WellsGA , BoersM , AnderssonN , HamelC , et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology2007;7:10. ">Shea 2007</a>) and listed the domains per review in <a href="#CD012103-tbl-0003">Table 3</a>. </p> <div class="table" id="CD012103-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">AMSTAR assessment per review</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Review no.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>First review author + year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Review title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AMSTAR criteria</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prespecified question and inclusion criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duplicate study selection and data extraction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comprehensive literature search</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grey literature included</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lists included and excluded studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Describes characteristics of included studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study quality assessed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies combined using appropriate methods</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Likelihood of publication bias considered/tested</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Potential for conflict of interest addressed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embryo freezing for preventing ovarian hyperstimulation syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA 563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TH1338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dopamine agonists for preventing ovarian hyperstimulation syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMA481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume expanders for the prevention of ovarian hyperstimulation syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MM1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotropin‐releasing hormone agonist versus hCG for oocyte triggering in antagonist‐assisted reproductive technology </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LDT1201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AWP1710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH versus daily FSH for women undergoing assisted reproduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate in combination with gonadotrophins for controlled ovarian stimulation in women undergoing in vitro fertilisation </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TA1860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0003" title="AllersmaT , FarquharC , CantineauAEP . Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010550.pub2] ">Allersma 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Natural cycle IVF for subfertile couples</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MV263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMY731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro fertilisation versus tubal re‐anastomosis (sterilisation reversal) for subfertility after tubal sterilisation </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ZP672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0013" title="PandianZ , GibreelA , BhattacharyaS . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003357.pub3] ">Pandian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro fertilisation for unexplained subfertility</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LA541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0002" title="AlbuquerqueLET , TsoLO , SaconatoH , AlbuquerqueMCRM , MacedoCR . Depot versus daily administration of gonadotrophin‐releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002808.pub3] ">Albuquerque 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depot versus daily administration of gonadotrophin‐releasing hormone<br/> agonist protocols for pituitary desensitisation in assisted reproduction<br/> cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WPM1780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0011" title="MartinsWP , VieiraADD , FigueiredoJBP , NastriCO . FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010042.pub2] ">Martins 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHH752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0010" title="KwanI , BhattacharyaS , KangA , WoolnerA . Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005289.pub3] ">Kwan 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMB1261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0004" title="BoomsmaCM , KeaySD , MacklonNS . Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005996.pub3] ">Boomsma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VJP951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0018" title="SiristatidisCS , BasiosG , PergialiotisV , VogiatziP . Aspirin for in vitro fertilisation. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD004832.pub4] ">Siristatidis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aspirin for in vitro fertilisation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CS1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0016" title="SiristatidisCS , MaheshwariA , BhattacharyaS . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006606.pub2] ">Siristatidis 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRS911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acupuncture and assisted reproductive technology</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MHM931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0012" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant luteinising hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KH291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Growth hormone for in vitro fertilisation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0017" title="Siristatidis CharalamposS , GibreelA , BasiosG , MaheshwariA , BhattacharyaS . Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2015, issue 11. [DOI: 10.1002/14651858.CD006919.pub4; CD006919] ">Siristatidis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>JC1630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0015" title="ShowellMG , BrownJ , ClarkeJ , HartRJ . Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD007807.pub2] ">Showell 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antioxidants for female subfertility</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>Search date: 24/07/2016.</p> <p>ART: artifical reproductive technology.</p> <p>FSH: follicle‐stimulating hormone.</p> <p>hCG: human chorionic gonadotrophin.</p> <p>ICSI: intracytoplasmic sperm injection.</p> <p>IUI: intrauterine insemination.</p> <p>IVF: in vitro fertilisation.</p> <p>NA: not applicable.</p> <p>rLH: recombinant luteinising hormone.</p> </div> </div> <p> <ul id="CD012103-list-0008"> <li> <p>All reviews had prespecified their clinical question and inclusion criteria.</p> </li> <li> <p>All reviews conducted study selection and data extraction in duplicate.</p> </li> <li> <p>All reviews conducted a comprehensive literature search.</p> </li> <li> <p>All reviews included searches of grey literature.</p> </li> <li> <p>All reviews listed included and excluded studies.</p> </li> <li> <p>All reviews described the characteristics of included studies.</p> </li> <li> <p>All reviews assessed study quality.</p> </li> <li> <p>All reviews combined studies using appropriate methods.</p> </li> <li> <p>A total of 25/27 reviews addressed the risk of reporting bias by using a statistical test when appropriate. </p> </li> <li> <p>All reviews addressed the potential for conflict of interest.</p> </li> </ul> </p> </section> </section> <section id="CD012103-sec-0046"> <h3 class="title" id="CD012103-sec-0046">Effect of interventions</h3> <p>We categorised all included intervention reviews by effectiveness for reduction of OHSS and by effectiveness for the primary pregnancy outcome stated in the review. In total, with regard to reduction of OHSS rates, seven reviews showed a beneficial effect of the intervention on the incidence of OHSS, one was promising,13 were ineffective and six remained inconclusive. Of the effective interventions, one intervention did reduce OHSS rates but had a detrimental effect on pregnancy outcomes (<a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a>). </p> <p>We listed effects of the interventions on the incidence of OHSS in the 'Summary of findings' table (<a href="#CD012103-tbl-0004">Table 4</a>). Most reviews did not report the incidence of OHSS as the (sole) primary outcome. This implies that the effectiveness of studied interventions can very well be different for the main primary outcome and for reduction of OHSS. Among the 25 non‐empty reviews, the effect of the intervention on OHSS rates was beneficial in eight reviews, and the intervention had no effect on OHSS rates in 14 reviews. One review reported that the control group had lower OHSS rates than the intervention group; however, the only primary study in this review reporting on OHSS did not provide exact numbers, so we could not calculate the effect size (<a href="./references#CD012103-bbs2-0018" title="SiristatidisCS , BasiosG , PergialiotisV , VogiatziP . Aspirin for in vitro fertilisation. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD004832.pub4] ">Siristatidis 2016</a>). For three reviews, we could not calculate effect size because they included insufficient primary studies reporting on OHSS (<a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a>; <a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a>; <a href="./references#CD012103-bbs2-0015" title="ShowellMG , BrownJ , ClarkeJ , HartRJ . Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD007807.pub2] ">Showell 2013</a>). </p> <div class="table" id="CD012103-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of findings for OHSS: per review and/or per intervention</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review title and</b> </p> <p><b>comparison intervention/control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> <p><b>with intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> <p><b>(studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence</b> </p> <p><b>(GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embryo freezing for preventing ovarian hyperstimulation syndrome</p> <p><i>(Embryo freezing vs fresh transfer)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 60 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 125 per 1000</p> <p>(62 to 240)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.12</p> <p>(0.01 to 2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Evidence based on a single open‐label study with insufficient methodological details provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embryo freezing for preventing ovarian hyperstimulation syndrome</p> <p><i>(Embryo freezing vs intravenous albumin)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS:</p> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS:</p> <p>308 per 1000</p> <p>(41 to 824)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 5.33</p> <p>(0.51 to 56.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Evidence based on a single open‐label trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS:</p> <p>265 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS:</p> <p>58 per 1000</p> <p>(11 to 241)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.17</p> <p>(0.03 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Evidence based on a single conference abstract<br/> Insufficient methodological details provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dopamine agonists for preventing ovarian hyperstimulation syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or severe OHSS: 286 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or severe OHSS: 97 per 1000</p> <p>(71 to 135)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.27</p> <p>(0.19 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2091</p> <p>(16 studies))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Lack of details for allocation concealment and blinding, selective reporting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume expanders for the prevention of ovarian hyperstimulation syndrome</p> <p><i>(human albumin vs placebo/no treatment)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or severe OHSS:</p> <p>122 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or severe OHSS: 85 per 1000 (61 to 177)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0,67</p> <p>(0.47 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1452</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Lack of details on allocation concealment and selective reporting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume expanders for the prevention of ovarian hyperstimulation syndrome</p> <p><i>(HES vs placebo)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS: 164 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS: 50 per 1000</p> <p>(23 to 104)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.27</p> <p>(0.12 to 0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Lack of details on allocation concealment and selective reporting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume expanders for the prevention of ovarian hyperstimulation syndrome</p> <p><i>(mannitol vs placebo)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS: 517 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS: 289 per 1000</p> <p>(191 to 407)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.38</p> <p>(0.22 to 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Lack of details on allocation concealment and selective reporting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles <i>(r‐hCG vs u‐hCG)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 27 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:40 per 1000</p> <p>(15 to 102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.39</p> <p>(0.25 to 0.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>374</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>One of the trials lacked methodological details on randomisation, allocation concealment and blinding </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles <i>(r‐LH vs u‐hCG)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 10 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>17 per 1000</p> <p>(11 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.76</p> <p>(0.37 to 8.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>417</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>One of the trials lacked adequate methodological details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotropin‐releasing hormone agonist versus hCG for oocyte triggering in antagonist‐assisted reproductive technology </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 5 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>1 per 1000</p> <p>(0 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.15</p> <p>(0.05 to 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>989</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>All studies at high risk of bias in 1 or more domains</p> <p>None clearly reported blinded outcome assessment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 270 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 97 per 1000</p> <p>(62 to 153)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.29</p> <p>(0.18 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>798</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH versus daily FSH for women undergoing assisted reproduction</p> <p>(<i>low dose</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 47 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 57 per 1000</p> <p>(26 to 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.22</p> <p>(0.56 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>645</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH versus daily FSH for women undergoing assisted reproduction</p> <p>(<i>medium dose</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 63 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 60 per 1000 (45 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.96</p> <p>(0.68 to 1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3075</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Confidence intervals compatible with clinically meaningful benefit in either arm or with no effect, plus high risk of attrition bias in 2 studies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH versus daily FSH for women undergoing assisted reproduction</p> <p>(<i>high dose</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.73</p> <p>(0.09 to 32.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>High risk of attrition bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation </p> <p><i>(clomiphene + gonadotropins vs gonadotropins)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 50 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:12 per 1000</p> <p>(5 to 27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.23</p> <p>(0.1 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1559</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Very wide 95% confidence interval crossing the threshold points of appreciable benefit or harm, which is 25% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0003" title="AllersmaT , FarquharC , CantineauAEP . Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010550.pub2] ">Allersma 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Natural cycle IVF for subfertile couples</p> <p><i>(natural cycle vs conventional IVF)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 67 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>13 per 1000</p> <p>(1 to 393)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.10</p> <p>(0.01 to 4.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Only 1 study reporting on OHSS</p> <p>Allocation concealment method not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> <p><i>(hCG versus placebo/no treatment)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 41 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>155 per 100</p> <p>(76 to 292)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 4.28</p> <p>(1.191 to 9.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>387</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Poor reporting of study methods</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> <p><i>(progesterone vs hCG regimens)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 126 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 72 per 1000</p> <p>(31 to 162)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.54</p> <p>(0.22 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>615</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Poor reporting of study methods</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> <p><i>(progesterone + GnRH agonist)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 50 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 50 per 1000</p> <p>(17 to 137)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.00</p> <p>(0.33 to 3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Poor reporting of study methods</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> <p><i>(progesterone vs progesterone + oestrogens)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 39 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 22 per 1000</p> <p>(8 to 62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.56</p> <p>(0.2 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Poor reporting of study methods</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology</p> <p><i>(GnRH antagonist vs GnRH agonist)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 114 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 73 per 1000</p> <p>(62 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.61<br/> (0.51 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7944</p> <p>(36 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methodological limitations including poor allocation concealment and lack of blinding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation </p> <p><i>(IVF vs tubal reanastomosis)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Empty review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0013" title="PandianZ , GibreelA , BhattacharyaS . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003357.pub3] ">Pandian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro fertilisation for unexplained subfertility</p> <p><i>(IVF vs IUI + gonadotropins/clomiphene citrate)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 58 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 66 per 1000</p> <p>(26 to 158)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.15 (0.43 to 3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Only 2 studies on OHSS reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0002" title="AlbuquerqueLET , TsoLO , SaconatoH , AlbuquerqueMCRM , MacedoCR . Depot versus daily administration of gonadotrophin‐releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002808.pub3] ">Albuquerque 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles </p> <p><i>(depot vs daily gonadotropins)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 3 per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 2 per 100<br/> (1 to 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.84<br/> (0.29 to 2.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>570</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most studies were classified as at unclear risk of bias for all domains</p> <p>Imprecision, number of events &lt; 300<br/> Studies were insufficient to assess publication bias </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles </p> <p><i>(rFSH vs HMG/HMG‐HP)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 17 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 17 per 1000</p> <p>(10 to 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.00</p> <p>(0.58 to 1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3197</p> <p>(11 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles </p> <p><i>(rFSH vs FSH‐P)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 28 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:49 per 1000</p> <p>(25 to 95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.79</p> <p>(0.89 to 3.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1490</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles </p> <p><i>(rFSH vs FSH‐HP)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 28 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>31 per 1000</p> <p>(20 to 48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.11</p> <p>(0.70 vs 1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3053</p> <p>(14 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two additional trials excluded in sensitivity analyses because it was unclear if data were reported according to ITT analysis (those were included for "Overall OHSS") </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles </p> <p><i>(rec‐hCG vs u‐hCG)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 19 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>22 per 1000</p> <p>(16 to 30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.18 (0.86 vs 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7740</p> <p>(32 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0011" title="MartinsWP , VieiraADD , FigueiredoJBP , NastriCO . FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010042.pub2] ">Martins 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques </p> <p><i>(low‐dose hCG vs FSH in late follicular phase)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 3 per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 1 per 100</p> <p>(0 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.30 (0.06 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>351</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Inconsistency, high risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral contraceptive pill, progestogen or oestrogen pre‐ treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques </p> <p><i>(OAC plus antagonist vs antagonist)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 17 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 25 per 1000</p> <p>(5 to 133)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.5 (0.26 to 8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single study reporting on OHSS</p> <p>Imprecision, number of events &lt; 300</p> <p>Wide confidence intervals that cross line of no effect</p> <p>High risk of attrition bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral contraceptive pill, progestogen or oestrogen pre‐ treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques </p> <p><i>(OAC plus antagonist vs agonist)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 55 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 35 per 1000</p> <p>(12 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.63</p> <p>(0.21 to 1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>One study at high risk of attrition bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0010" title="KwanI , BhattacharyaS , KangA , WoolnerA . Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005289.pub3] ">Kwan 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Monitoring of stimulated cycles in assisted reproduction</p> <p>(IVF and ICSI)</p> <p><i>(transvaginal ultrasound + estradiol vs transvaginal ultrasound)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 36 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 36 per 1000</p> <p>(18 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.03</p> <p>(0.48 to 2.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>781</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300 with wide confidence intervals</p> <p>Methods of randomisation inadequately described in 3 of 6 trials, allocation concealment inadequately described in all 6 trials and blinding inadequately described in 5 of 6 trials </p> <p>No definition of OHSS provided by authors of these 6 studies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0004" title="BoomsmaCM , KeaySD , MacklonNS . Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005996.pub3] ">Boomsma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles </p> <p><i>(adjuvant glucocorticoids vs no glucocorticoids)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 194 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 159 per 1000</p> <p>(64 to 392)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.82 (0.33 to 2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0018" title="SiristatidisCS , BasiosG , PergialiotisV , VogiatziP . Aspirin for in vitro fertilisation. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD004832.pub4] ">Siristatidis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aspirin for in vitro fertilisation</p> <p><i>(aspirin vs no treatment/placebo)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 1 study reported on OHSS; no exact numbers or explanation of numerators/denominators given </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0016" title="SiristatidisCS , MaheshwariA , BhattacharyaS . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006606.pub2] ">Siristatidis 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction </p> <p><i>(IVM vs conventional IVF)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Empty review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acupuncture and assisted reproductive technology</p> <p><i>(acupuncture vs no acupuncture/sham acupuncture)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies reported on OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0012" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles </p> <p><i>(combined rLH + FSH vs FSH )</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 20 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>27 per 1000</p> <p>(12 to 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.34</p> <p>(0.58 to 3.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>986</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Some methodological details unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Growth hormone for in vitro fertilization</p> <p><i>(growth hormone vs no treatment/placebo)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 1 study reported on OHSS; however, no cases of OHSS were reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0017" title="Siristatidis CharalamposS , GibreelA , BasiosG , MaheshwariA , BhattacharyaS . Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2015, issue 11. [DOI: 10.1002/14651858.CD006919.pub4; CD006919] ">Siristatidis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotropin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction </p> <p><i>(different protocols vs other protocol)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 20 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 27 per 1000</p> <p>(12 to 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.34</p> <p>(0.58 to 3.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>986</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Some methodological details unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0015" title="ShowellMG , BrownJ , ClarkeJ , HartRJ . Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD007807.pub2] ">Showell 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antioxidants for female subfertility</p> <p><i>(antioxidants vs no treatment/placebo/other antioxidant)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Although 3 studies reported on OHSS, no numbers were given, so effect size could not be calculated </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Review authors GRADED these outcomes as 'high quality'; however, the total event rate &lt; 300 would justify downgrading for this to moderate‐quality evidence. </p> <p>ART: artifical reproductive technology.</p> <p>FSH: follicle‐stimulating hormone.</p> <p>FSH‐HP: highly purified FSH.</p> <p>hCG: human chorionic gonadotrophin.</p> <p>HES: hydroxyethyl starch.</p> <p>ICSI: intracytoplasmic sperm injection.</p> <p>IUI: intrauterine insemination.</p> <p>IVF: in vitro fertilisation.</p> <p>IVM: in vitro maturation.</p> <p>NA: not applicable.</p> <p>OAC: oral anticoagulant.</p> <p>OHSS: ovarian hyperstimulation syndrome.</p> <p>OR: odds ratio.</p> <p>rFSH: recombinant follicle‐stimulating hormone.</p> <p>r‐hCG: recombinant human chorionic gonadotrophin.</p> <p>rLH: recombinant luteinising hormone.</p> <p>Total: any grade of OHSS.</p> <p>u‐hCG: urinary human chorionic gonadotrophin.</p> </div> </div> <p>We summarise here the effectiveness of interventions for both reduction of OHSS and pregnancy outcomes, ranked by timing of the intervention within an ART cycle. </p> <p>Moreover, for interventions that had a beneficial effect on OHSS rate, <a href="#CD012103-fig-0002">Figure 2</a> shows the extent of this effect in relation to the effect on live birth rate (when reported) or clinical pregnancy. </p> <div class="figure" id="CD012103-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Extent of effect of interventions on OHSS rate and live birth rate (when reported) or clinical pregnancy: OR and 95% CI." data-id="CD012103-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012103.pub2/media/CDSR/CD012103/image_n/nCD012103-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Extent of effect of interventions on OHSS rate and live birth rate (when reported) or clinical pregnancy: OR and 95% CI. </p> </div> </div> </div> <section id="CD012103-sec-0047"> <h4 class="title">Effective interventions for reduction of OHSS with no impact on nor improvement in pregnancy outcomes </h4> <section id="CD012103-sec-0048"> <h5 class="title">Pretreatment adjuvant therapy</h5> <p> <ul id="CD012103-list-0009"> <li> <p>Metformin treatment before and during IVF or ICSI in women with PCOS: No conclusive evidence suggests that metformin treatment before or during ART cycles improved live birth rates (low‐quality evidence). However, use of this insulin‐sensitising agent increased clinical pregnancy rates and decreased the risk of OHSS (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a>). Evidence showed a beneficial effect of the intervention on OHSS rates. </p> </li> </ul> </p> </section> <section id="CD012103-sec-0049"> <h5 class="title">Pituitary downregulation phase</h5> <p> <ul id="CD012103-list-0010"> <li> <p>Gonadotrophin‐releasing hormone (GnRH) antagonists for ART: Use of antagonists compared with long GnRHa protocols was associated with a large reduction in OHSS, and no evidence suggested a difference in live birth rates (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a>). Evidence showed a beneficial effect of the intervention on OHSS rates. </p> </li> </ul> </p> </section> <section id="CD012103-sec-0050"> <h5 class="title">Stimulation phase</h5> <p> <ul id="CD012103-list-0011"> <li> <p>Clomiphene citrate for controlled ovarian stimulation in women undergoing IVF: This review suggested that regimens with clomiphene could be used in controlled ovarian stimulation for IVF treatment without a reduction in pregnancy rates. However, further evidence is required before these regimens can be recommended with confidence as alternatives to gonadotrophins alone in GnRH long or short protocols (low‐quality evidence) (<a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a>). Evidence showed a beneficial effect of the intervention on OHSS rates. </p> </li> </ul> </p> </section> <section id="CD012103-sec-0051"> <h5 class="title">Ovulation trigger phase</h5> <p> <ul id="CD012103-list-0012"> <li> <p>Dopamine agonists for preventing OHSS: Dopamine agonists appeared to reduce the risk of OHSS in high‐risk women, especially for moderate OHSS. Use of dopamine agonists did not appear to affect clinical pregnancy rates or miscarriage rates, nor did they increase the risk of other adverse events (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a>). Evidence showed a beneficial effect of the intervention on moderate or severe OHSS rates. </p> </li> <li> <p>Volume expanders for prevention of OHSS: The volume expanders hydroxyethyl starch and mannitol decreased the incidence of moderate or severe OHSS without affecting pregnancy rates (very low‐quality evidence) (<a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a>). Evidence showed a beneficial effect of the intervention on moderate or severe OHSS rates. </p> </li> </ul> </p> </section> <section id="CD012103-sec-0052"> <h5 class="title">Luteal support phase</h5> <p> <ul id="CD012103-list-0013"> <li> <p>Luteal support phase in ART cycles: This review concluded that progesterone appears to provide the best method of providing luteal phase support, as it is associated with higher rates of live birth or ongoing pregnancy than placebo, and lower rates of OHSS than hCG. Addition of one or more doses of GnRH agonists to progesterone was associated with higher live birth and ongoing pregnancy rates than progesterone alone. Overall, addition of other substances such as oestrogen or hCG did not seem to improve outcomes, and hCG was associated with higher risk of OHSS. The route of progesterone administration did not seem to matter (quality of evidence was low for most comparisons) (<a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a>). Evidence showed a beneficial effect of the intervention on OHSS rates for the comparison hCG versus placebo/no treatment. For the other comparisons, no evidence showed an effect on OHSS rates. </p> </li> </ul> </p> </section> </section> <section id="CD012103-sec-0053"> <h4 class="title">Effective interventions for reduction of OHSS with negative impact on pregnancy outcomes</h4> <section id="CD012103-sec-0054"> <h5 class="title">Ovulation trigger phase</h5> <p> <ul id="CD012103-list-0014"> <li> <p>GnRHa versus hCG for oocyte triggering in antagonist ART cycles: Evidence suggested a lower live birth rate, a reduced ongoing pregnancy rate and a higher miscarriage rate among women who received a GnRHa. However, OHSS rates were reduced with GnRHa triggering; therefore, clinicians should consider the tradeoff between benefits and harms (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a>). Evidence showed a beneficial effect of the intervention on OHSS rates. </p> </li> <li> <p>Volume expanders for prevention of OHSS: Evidence suggested that human albumin decreased the incidence of moderate or severe OHSS. However, contrary to the (very low‐quality) evidence found with hydroxyethyl starch (HES) and mannitol, human albumin appeared to have a detrimental effect on pregnancy rates (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012103-sec-0055"> <h4 class="title">Promising interventions for reduction of OHSS with no impact on or improvement in pregnancy outcomes (more evidence needed) </h4> <section id="CD012103-sec-0056"> <h5 class="title">Ovulation trigger phase</h5> <p> <ul id="CD012103-list-0015"> <li> <p>Coasting (withholding gonadotrophins) for preventing OHSS: Evidence was insufficient to show benefit derived from coasting done to prevent OHSS compared with no coasting or other interventions (very low‐quality evidence) (<a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a>). Evidence showed a beneficial effect of the intervention on OHSS rates, but this was reported only in a single abstract on an RCT that provided insufficient methodological details. </p> </li> </ul> </p> </section> </section> <section id="CD012103-sec-0057"> <h4 class="title">Ineffective interventions for reduction of OHSS with no impact on or improvement in pregnancy outcomes </h4> <section id="CD012103-sec-0058"> <h5 class="title">Pretreatment adjuvant therapy</h5> <p> <ul id="CD012103-list-0016"> <li> <p>Oral contraceptive pill (OCP), progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing ARTs: Evidence suggested improved pregnancy outcomes with progestogen pretreatment and poorer pregnancy outcomes with combined OCP pretreatment (<a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> </ul> </p> </section> <section id="CD012103-sec-0059"> <h5 class="title">Pituitary downregulation phase</h5> <p> <ul id="CD012103-list-0017"> <li> <p>GnRHa protocols for pituitary suppression in ART cycles: The pregnancy rate was higher when GnRHa was used in a long protocol as compared with a short or ultra‐short protocol (low‐quality evidence) (<a href="./references#CD012103-bbs2-0017" title="Siristatidis CharalamposS , GibreelA , BasiosG , MaheshwariA , BhattacharyaS . Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2015, issue 11. [DOI: 10.1002/14651858.CD006919.pub4; CD006919] ">Siristatidis 2015</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> <li> <p>Depot versus daily administration of GnRHa protocols for pituitary desensitisation in assisted reproduction cycles: No evidence suggested a significant difference in live birth or pregnancy outcomes between depot and daily GnRHa use for pituitary downregulation in IVF cycles using the long protocol, but substantial differences could not be ruled out (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0002" title="AlbuquerqueLET , TsoLO , SaconatoH , AlbuquerqueMCRM , MacedoCR . Depot versus daily administration of gonadotrophin‐releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002808.pub3] ">Albuquerque 2013</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> </ul> </p> </section> <section id="CD012103-sec-0060"> <h5 class="title">Stimulation phase</h5> <p> <ul id="CD012103-list-0018"> <li> <p>FSH replaced by low‐dose hCG in the late follicular phase versus FSH alone for ARTs: Review authors were very uncertain about effects on live birth, OHSS and miscarriage, but evidence suggested that this intervention did not reduce the chances of ongoing and clinical pregnancy, and that it was likely to result in retrieval of an equivalent number of oocytes with less FSH expended (very low‐quality evidence) (<a href="./references#CD012103-bbs2-0011" title="MartinsWP , VieiraADD , FigueiredoJBP , NastriCO . FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010042.pub2] ">Martins 2013</a>). No evidence showed an effect of the intervention on OHSS rate. </p> </li> <li> <p>Recombinant versus urinary gonadotrophin for ovarian stimulation in ART cycles: It appeared that all available gonadotrophins were equally effective and safe. The choice of one or the other product would depend upon the availability of the product, the convenience of its use and associated costs. Any specific differences are likely to be too small to justify further research (high‐quality evidence) (<a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> <li> <p>Long‐acting FSH versus daily FSH for women undergoing assisted reproduction: A medium dose (150 to 180 μg) of long‐acting FSH appeared to offer a safe treatment option that was as effective as daily FSH in women with unexplained subfertility. Evidence showed a reduced live birth rate among women receiving a low dose (60 to 120 μg) of long‐acting FSH compared with daily FSH (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> <li> <p>Natural cycle IVF for subfertile couples: No evidence showed a significant difference between natural cycle and standard IVF for outcomes including live birth, OHSS, clinical pregnancy and multiple pregnancy (very low‐quality evidence) (<a href="./references#CD012103-bbs2-0003" title="AllersmaT , FarquharC , CantineauAEP . Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010550.pub2] ">Allersma 2013</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> <li> <p>Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI): RCTs provided no evidence to support cycle monitoring by ultrasonography plus serum oestradiol as more efficacious than cycle monitoring by ultrasonography only for the outcomes of live birth and pregnancy. A large well‐designed RCT is needed (low‐quality evidence) (<a href="./references#CD012103-bbs2-0010" title="KwanI , BhattacharyaS , KangA , WoolnerA . Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005289.pub3] ">Kwan 2014</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> </ul> </p> </section> <section id="CD012103-sec-0061"> <h5 class="title">Ovulation trigger phase</h5> <p> <ul id="CD012103-list-0019"> <li> <p>Recombinant versus urinary hCG for final oocyte maturation triggering in IVF and ICSI cycles: Review authors concluded that urinary hCG remains the best choice for final oocyte maturation triggering in IVF and ICSI treatment cycles owing to availability and cost and no difference in live birth rates (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> </ul> </p> </section> <section id="CD012103-sec-0062"> <h5 class="title">Embryo transfer phase</h5> <p> <ul id="CD012103-list-0020"> <li> <p>Peri‐implantation glucocorticoid administration for ART cycles: Overall, no clear evidence suggests that administration of peri‐implantation glucocorticoids in ART cycles significantly improved clinical outcomes (low‐quality evidence) (<a href="./references#CD012103-bbs2-0004" title="BoomsmaCM , KeaySD , MacklonNS . Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005996.pub3] ">Boomsma 2012</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> <li> <p>Embryo freezing for prevention of OHSS: Evidence was insufficient to show benefit for routine cryopreservation and the relative merits of intravenous albumin versus cryopreservation (low‐quality evidence) (<a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> </ul> </p> </section> <section id="CD012103-sec-0063"> <h5 class="title">Luteal support phase</h5> <p> <ul id="CD012103-list-0021"> <li> <p>Recombinant luteinising hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles: No evidence suggested that coadministration of rLH and recombinant follicle‐stimulating hormone (rFSH) in GnRHa‐downregulated women resulted in more live births than were reported with controlled ovarian hyperstimulation (COH) with rFSH alone. Nevertheless, all pooled pregnancy estimates, although not significantly different, pointed towards a beneficial effect of cotreatment with rLH, in particular with respect to pregnancy loss (low‐quality evidence) (<a href="./references#CD012103-bbs2-0012" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> </ul> </p> </section> <section id="CD012103-sec-0064"> <h5 class="title">ART versus other interventions</h5> <p> <ul id="CD012103-list-0022"> <li> <p>In vitro fertilisation for unexplained subfertility: IVF may be more effective than IUI plus ovarian stimulation (low‐quality evidence) (<a href="./references#CD012103-bbs2-0013" title="PandianZ , GibreelA , BhattacharyaS . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003357.pub3] ">Pandian 2015</a>). No evidence showed an effect of the intervention on OHSS rates. </p> </li> </ul> </p> </section> </section> <section id="CD012103-sec-0065"> <h4 class="title">Possibly ineffective interventions for reduction of OHSS with no impact on or improvement in pregnancy outcomes (more evidence needed) </h4> <p> <ul id="CD012103-list-0023"> <li> <p>None were reported.</p> </li> </ul> </p> </section> <section id="CD012103-sec-0066"> <h4 class="title">No conclusions possible on effectiveness for reduction of OHSS (lack of evidence)</h4> <p>For six reviews, review authors could provide no conclusions on the effects of interventions on OHSS rates. </p> <section id="CD012103-sec-0067"> <h5 class="title">Pretreatment adjuvant therapy</h5> <p> <ul id="CD012103-list-0024"> <li> <p>Aspirin for IVF: Evidence from adequately powered RCTs was insufficient for review authors to reach a conclusion (<a href="./references#CD012103-bbs2-0018" title="SiristatidisCS , BasiosG , PergialiotisV , VogiatziP . Aspirin for in vitro fertilisation. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD004832.pub4] ">Siristatidis 2016</a>). No evidence showed an effect of the intervention on OHSS rates. No numbers were provided, so we could not calculate effect size. </p> </li> <li> <p>Antioxidants for female subfertility: Antioxidants were not associated with increased live birth or clinical pregnancy rates, although more evidence is needed (low‐quality evidence) (<a href="./references#CD012103-bbs2-0015" title="ShowellMG , BrownJ , ClarkeJ , HartRJ . Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD007807.pub2] ">Showell 2013</a>). No trials reported actual numbers of cases of OHSS. </p> </li> <li> <p>Acupuncture and ART: No evidence suggested benefit for acupuncture in improving live birth or clinical pregnancy rates in assisted conception (low‐quality evidence) (<a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a>). No trials reported on OHSS. </p> </li> </ul> </p> </section> <section id="CD012103-sec-0068"> <h5 class="title">Stimulation phase</h5> <p> <ul id="CD012103-list-0025"> <li> <p>Growth hormone for IVF: We could not calculate the effect of the intervention on OHSS rates. Use of growth hormone in poor responders was associated with significant improvement in live birth rates (moderate‐quality evidence) (<a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a>). </p> </li> </ul> <ul id="CD012103-list-0026"> <li> <p>In vitro maturation in subfertile women with polycystic ovarian syndrome (PCOS) undergoing assisted reproduction: This is an empty review (<a href="./references#CD012103-bbs2-0016" title="SiristatidisCS , MaheshwariA , BhattacharyaS . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006606.pub2] ">Siristatidis 2009</a>). </p> </li> </ul> </p> </section> <section id="CD012103-sec-0069"> <h5 class="title">ART versus other interventions</h5> <p> <ul id="CD012103-list-0027"> <li> <p>IVF versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation: This is an empty review (<a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a>). </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012103-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012103-sec-0070"></div> <section id="CD012103-sec-0071"> <h3 class="title" id="CD012103-sec-0071">Summary of main results</h3> <p>We found seven interventions that were effective in reducing the occurrence of ovarian hyperstimulation syndrome (OHSS) while not influencing or even improving pregnancy outcomes: metformin pretreatment in women with polycystic ovary syndrome (PCOS), use of a gonadotrophin‐releasing hormone (GnRH) antagonist protocol for pituitary suppression, use of clomiphene citrate for controlled ovarian stimulation, use of dopamine agonists and the volume expanders hydroxyethyl starch (HES) and mannitol around the time of oocyte triggering, coasting before oocyte triggering and use of progesterone for luteal phase support (<a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a>; <a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a>; <a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a>; <a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a>; <a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a>; <a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a>; <a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a>). </p> <p>Two additional interventions ‐ gonadotrophin‐releasing agonist (GnRHa) versus human chorionic gonadotrophin (hCG) for oocyte triggering, and use of the volume expander human albumin around the time of ovulation triggering ‐ proved effective in reducing OHSS but negatively impacted pregnancy outcomes in autologous cycles (<a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a>; <a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a>). </p> <p>Concerning the GnRHa trigger, this detrimental effect on pregnancy outcomes was not found in oocyte donation cycles. This would make the use of GnRHa for ovulation triggering suitable for oocyte donation programmes, as it would largely eradicate the chance of OHSS in the donor, without negatively influencing pregnancy outcomes in the recipient. GnRHa could also be useful in preventing OHSS in "freeze‐all" programmes (i.e. embryo transfer is not performed in the fresh autologous cycle) ‐ a regimen that is currently the topic of numerous research projects and new randomised controlled trials (RCTs). </p> </section> <section id="CD012103-sec-0072"> <h3 class="title" id="CD012103-sec-0072">Overall completeness and applicability of evidence</h3> <p>This overview of Cochrane reviews is complete and up‐to‐date as of December 2016. Only four reviews specifically addressed prevention of OHSS; by reporting all reviews on assisted reproduction technology (ART) that include OHSS as a primary or secondary outcome, we aimed to provide the most up‐to‐date overview of strategies to prevent OHSS currently included within the Cochrane Library. In keeping with the nature of a Cochrane overview, this body of work does not cover non‐Cochrane reviews on OHSS. Moreover, alternative or emerging strategies for prevention of OHSS may not yet have been covered in a Cochrane review and therefore cannot be found in this overview, for example, use of calcium gluconate infusion or the dual GnRHa and hCG trigger. Once such strategies have been assessed in new reviews, we can and will update this overview accordingly. </p> <p>Clinically relevant moderate OHSS and severe OHSS are still rare conditions; moreover, inclusion of 'high risk' groups was not based on a variety of criteria and was not a prerequisite at all for many of the included reviews. In combination with the fact that most studies included OHSS as a secondary outcome, this means that most primary studies lacked statistical power to report on OHSS. However, as OHSS is an undesirable outcome in ART, it is unlikely that the prevalence will change, and it is considered unethical by many institutional ethics review boards to randomise very high‐risk groups as a control in current and future studies. Unfortunately, this means that it will be difficult to nearly impossible for researchers to perform well‐powered studies that address these shortcomings. </p> <p>A major limitation of many of the included reviews is reporting of 'total OHSS' only. A total of three reviews reported separately on the subgroups 'moderate' and 'severe' OHSS. Three additional reviews reported only 'severe' OHSS; the remaining 21 reviews described that they reported on total 'OHSS' and provided no further explanation (e.g. this could have included moderate + severe, mild + moderate + severe, severe only). As almost all hyperstimulation cycles for in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) are accompanied by some form of discomfort and ovarian enlargement, the subgroup 'mild OHSS' does not seem to represent a very significant clinical outcome (for a description of subgroups, see <a href="./appendices#CD012103-sec-0082">Appendix 1</a>). Reporting only on the total incidence of OHSS with no further specification of cases per subgroup biases the comparability of studies and actual reporting on clinically significant OHSS rates. For example, some studies could have found mainly, or only, mild cases of OHSS, whereas other studies might not have even included or assessed mild cases and would have reported only moderate and/or severe cases of OHSS. This would mean that the former study would overestimate the number of OHSS cases for which the latter finding is more precise. Also, a study that reports only on <i>hospitalised</i> cases might underestimate moderate cases, which we consider clinically significant too. Moreover, reviews reporting on interventions that aim to reduce the incidence of OHSS included only 'high risk' populations, whereas most of the other reviews did not select their population specifically for this criterion, which makes it difficult to compare the effectiveness of different interventions within this overview. This heterogeneous method of reporting fails to acknowledge the incidence of moderate and severe cases, resulting in an evidence gap for this important adverse outcome of ART cycles. </p> <p>Currently, many ART clinics apply preventive strategies such as natural cycle/mild stimulation IVF or cryopreservation of all embryos (the 'freeze‐all' approach) that have not been proven to have a beneficial effect on OHSS on the basis of low‐quality evidence (<a href="./references#CD012103-bbs2-0003" title="AllersmaT , FarquharC , CantineauAEP . Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010550.pub2] ">Allersma 2013</a>; <a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a>; <a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a>). However, theoretical considerations suggest that these strategies are probably effective, as they eliminate certain steps of an ART cycle (preventing multiple follicle growth and implantation, thereby preventing an hCG surge); additional RCTs are needed to provide a robust evidence base for these practices. </p> </section> <section id="CD012103-sec-0073"> <h3 class="title" id="CD012103-sec-0073">Quality of the evidence</h3> <p>All included systematic reviews were prepared according to Cochrane guidelines and were of high quality in most respects, although only 17 of 27 had conducted a literature search within the past three years. Moreover, the included primary studies might be significantly older than the review publication date, thus sometimes reflecting outdated clinical practice or stimulation regimens. This cannot be avoided in an overview, as we summarise available evidence from existing reviews, and sometimes few or no recent RCTs are available. </p> <p>This also has an impact on the quality of the evidence reported by primary studies in the included reviews. Using GRADE methods, we rated this quality level as very low to high. The main reasons for downgrading the quality of evidence included bias in the primary studies (inadequate reporting of allocation concealment and randomisation methods, lack of blinding) and imprecision. Evidence was frequently restricted to that provided by only a few included trials per comparison. Because clinically relevant OHSS is still a relatively rare outcome in ART cycles, and given that the primary study size and the number of studies per comparison have been limited for most reviews, the event rate of reported OHSS will remain low, as mild OHSS frequently is not reported. This implies that the quality of the evidence should be downgraded by one level (according to GRADE rules for downgrading dichotomous outcomes by one level for imprecision), and that the event rate &lt; 300 and the total cumulative sample size were lower than the calculated optimal information size (OIS) (<a href="./references#CD012103-bbs2-0090" title="SchünemannH , BrozekJ , GuyattG , OxmanA (editors) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated March 2013. http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html (accessed 15 November 2015). ">Schünemann 2013</a>). As a result, the quality of the evidence on effectiveness of interventions for the outcome of OHSS remains 'very low' or 'low' for most interventions and comparisons. </p> </section> <section id="CD012103-sec-0074"> <h3 class="title" id="CD012103-sec-0074">Potential biases in the overview process</h3> <p>We identified no biases during the overview process.</p> </section> <section id="CD012103-sec-0075"> <h3 class="title" id="CD012103-sec-0075">Agreements and disagreements with other studies or reviews</h3> <p>Over the years, as new evidence from RCTs continues to emerge, a steady stream of publications aims to provide a comprehensive overview on the pathophysiology, prevention and treatment of OHSS. For example, in 2016 alone, <a href="./references#CD012103-bbs2-0075" title="GuoJL , ZhangDD , ZhaoY , ZhangD , ZhangXM , ZhouCQ , et al. Pharmacologic interventions in preventing ovarian hyperstimulation syndrome: a systematic review and network meta‐analysis. Scientific Reports2016;11(6):19093.doi:10.1038/srep19093. ">Guo 2016</a> and <a href="./references#CD012103-bbs2-0082" title="KwikM , MaxwellE . Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome. Current Opinion in Obstetrics and Gynecology2016;28(4):236‐41. ">Kwik 2016</a> were published, and recently, the American Society for Reproductive Medicine provided practice guidelines (<a href="./references#CD012103-bbs2-0064" title="Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertility and Sterility2016;106(7):1634‐47. ">ASRM 2016</a>). In addition to this, an abundance of reviews have examined particular interventions covered in this overview, such as use of dopamine agonists (<a href="./references#CD012103-bbs2-0065" title="BaumgartenM , PolanskiL , CampbellB , Raine‐FenningN . Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta‐analysis. Human Fertility (Cambridge)2013;16(3):168‐74. ">Baumgarten 2013</a>; <a href="./references#CD012103-bbs2-0078" title="KalampokasT , CreatsasG , KalampokasE . Cabergoline as treatment of ovarian hyperstimulation syndrome: a review. Gynecological Endocrinology2013;29(2):98‐100. ">Kalampokas 2013</a>; <a href="./references#CD012103-bbs2-0079" title="KasumM , VrcicH , StanicP , JezekD , OreskovicS , Beketic‐OreskovicL , et al. Dopamine agonists in prevention of ovarian hyperstimulation syndrome. Gynecological Endocrinology2014;30(12):845‐9. ">Kasum 2015</a>; <a href="./references#CD012103-bbs2-0083" title="LeitaoVM , MoroniRM , SekoLM , NastriCo , MartinsWP . Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta‐analysis of randomized controlled trials. Fertility and Sterility2014;101(3):664‐75. ">Leitao 2014</a>). </p> <p>Such publications encompass, for example, regional or national clinical practice guidelines or an overview of the literature. However, most also include data derived from retrospective and population‐based longitudinal studies or non‐randomised controlled trials. To our knowledge, this overview is the first to include solely systematic reviews on ART conducted according to rigorous Cochrane standards, thus showing high methodological quality. Moreover, we included not only reviews of interventions directly aiming to prevent OHSS, but also reviews of other ART interventions reporting on OHSS as an adverse effect, thus presenting a more complete overview of the literature currently available in the Cochrane Library. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012103-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/media/CDSR/CD012103/urn:x-wiley:14651858:media:CD012103:CD012103-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/media/CDSR/CD012103/image_t/tCD012103-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of included reviews." data-id="CD012103-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012103.pub2/media/CDSR/CD012103/image_n/nCD012103-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of included reviews.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/media/CDSR/CD012103/image_n/nCD012103-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012103-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/media/CDSR/CD012103/urn:x-wiley:14651858:media:CD012103:CD012103-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/media/CDSR/CD012103/image_t/tCD012103-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Extent of effect of interventions on OHSS rate and live birth rate (when reported) or clinical pregnancy: OR and 95% CI." data-id="CD012103-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012103.pub2/media/CDSR/CD012103/image_n/nCD012103-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Extent of effect of interventions on OHSS rate and live birth rate (when reported) or clinical pregnancy: OR and 95% CI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/media/CDSR/CD012103/image_n/nCD012103-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD012103-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Review characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of included trials</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> <p><b><i>Definition of high risk for OHSS (where applicable)</i> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison intervention/control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review limitations</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA563</p> <p><a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a> </p> <p>Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>340 women with PCOS</p> <p>downregulated by GnRHa, undergoing superovulation in IVF or ICSI cycles</p> <p><i>High risk: women with PCOS</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coasting when</p> <p>oestradiol levels were &gt; 2500 pg/mL or &gt; 9000 pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Early unilateral follicular</p> <p>aspiration</p> <p>No coasting or other interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Number of oocytes retrieved</p> <p>Multiple pregnancy</p> <p>Miscarriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparisons based on limited trial data</p> <p>Live birth reported in only 1 trial</p> <p>Trials lacked blinding, and half the trials lacked details on allocation concealment and incomplete outcome assessment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA561</p> <p><a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a> </p> <p>Embryo freezing for preventing ovarian hyperstimulation syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151 women</p> <p>downregulated by GnRHa, undergoing superovulation in IVF or ICSI cycles.</p> <p><i>High risk: as defined by included studies</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cryopreservation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fresh embryo transfer</p> <p>Intravenous albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Clinical pregnancy<sup>a</sup> </p> <p>Live birth</p> <p>Admissions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence based on 2 trials, 1 for each comparison</p> <p>Live birth reported in only 1 trial</p> <p>Issues around methodological quality of both trials</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TH1338</p> <p><a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a> </p> <p>Dopamine agonists for preventing ovarian hyperstimulation syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2091 women at high risk of developing OHSS undergoing ART</p> <p><i>High risk: as defined by included studies</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cabergoline quinagolide, bromocriptine,</p> <p>cabergoline + albumin,</p> <p>cabergoline + HES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo/no treatment/other treatment:</p> <p>Albumin alone</p> <p>HES</p> <p>Coasting</p> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Adverse effects</p> <p>Miscarriage</p> <p>Multiple pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation concealment and blinding not adequately reported.</p> <p>One study used a co‐intervention of albumin IV and 1 of HES</p> <p>Different regimens of cabergoline administration between included studies</p> <p>Live birth rate reported in only 2 studies</p> <p>Incomplete reporting of multiple pregnancy rate, adverse effects and miscarriage rate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMA481</p> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> <p>Volume expanders for prevention of OHSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1660 (albumin) + 487 (HES) women</p> <p>at high risk of developing OHSS undergoing ART cycles <i>High risk: determined as number of follicles or oestradiol levels on day of hCG, as defined by included studies</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Human albumin</p> <p>Hydroxyethyl starch (HES)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Number of oocytes retrieved</p> <p>Multiple pregnancy</p> <p>Miscarriage</p> <p>Live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No reporting of live birth rate</p> <p>Limited by incomplete data reporting and lack of (details on) blinding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA413</p> <p><a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a> </p> <p>Recombinant vs urinary hCG for final oocyte maturation triggering in IVF and ICSI cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2952 women undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant hCG</p> <p>Recombinant LH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Miscarriage</p> <p>Oocytes retrieved</p> <p>Tolerance</p> <p>Live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Review authors combined ongoing pregnancy and live births together</p> <p>Only 7 trials reported on live birth</p> <p>Trials lacked details on allocation concealment, randomisation and blinding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MM1690</p> <p><a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a> </p> <p>GnRHa vs hCG for oocyte triggering in antagonist‐assisted reproductive technology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1847 women undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GnRH agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth rate<sup>a</sup> </p> <p>Ongoing pregnancy</p> <p>Clinical pregnancy</p> <p>Multiple pregnancy</p> <p>Miscarriage rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias in included studies. Limitations included premature termination, failure to clearly report methods and substantial heterogeneity </p> <p>Adverse events such as multiple pregnancy rate were not well reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AWP1710</p> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> <p>Long‐acting FSH vs daily FSH for women undergoing assisted reproduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3753 women with subfertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daily FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth rate<sup>a</sup> </p> <p>Ongoing pregnancy rate</p> <p>Clinical pregnancy rate</p> <p>Multiple pregnancy rate</p> <p>Miscarriage rate</p> <p>Adverse events</p> <p>Satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited by risk of attrition bias in some primary studies and by serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LDT120</p> <p><a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a> </p> <p>Metformin treatment before and during IVF or ICSI in women with PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>816 women with PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy<sup>a</sup> Miscarriage </p> <p>Adverse events Number of oocytes</p> <p>retrieved</p> <p>Total dose FSH (IU) Number of days</p> <p>gonadotrophin treatment</p> <p>Cycle cancellation rate</p> <p>Serum E2 level (nmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Half the trials were not blinded and lacked details on allocation concealment and randomisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM1335</p> <p><a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a> </p> <p>Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing IVF </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 RCTs,</p> <p>12 for meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2536 (12 trials)</p> <p>Subfertile women undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate</p> <p>± additional treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alternative treatments for</p> <p>COH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth rate<sup>a</sup> </p> <p>Miscarriage rate</p> <p>Ectopic pregnancy</p> <p>Foetal abnormality</p> <p>Ongoing pregnancy rate</p> <p>Cancellation rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth reported in only 5 trials</p> <p>Most studies suffered from suboptimal methods and information on some outcomes was insufficient </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TA1860</p> <p><a href="./references#CD012103-bbs2-0003" title="AllersmaT , FarquharC , CantineauAEP . Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010550.pub2] ">Allersma 2013</a> </p> <p>Natural cycle IVF for subfertile couples</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>382 subfertile women and couples undertaking IVF treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Natural cycle IVF</p> <p>Modified natural cycle IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COH IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Pregnancy</p> <p>Ongoing pregnancy</p> <p>Number of oocytes retrieved</p> <p>Time to live birth</p> <p>Number of cycles required to conceive</p> <p>Cumulative pregnancy/live birth rate</p> <p>Multiple pregnancy</p> <p>Lack of embryos for cryopreservation</p> <p>Cycle cancellation</p> <p>Gestational abnormalities</p> <p>Cancellation of treatment</p> <p>Cost‐effectiveness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Few studies, live birth reported in only 1 very small trial</p> <p>Inclusion criteria differed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MV263</p> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> <p>Luteal phase support for ART cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26,198 women with any cause of subfertility undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progesterone</p> <p>hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo or no treatment</p> <p>hCG</p> <p>Progesterone + oestrogen Progesterone + GnRHa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Ongoing pregnancy</p> <p>Miscarriage</p> <p>OHSS</p> <p>Multiple pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor reporting of study methods and imprecision due to small sample sizes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA412</p> <p><a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a> </p> <p>Gonadotrophin‐releasing hormone antagonists for ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,212 women undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GnRH antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐course GnRHa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Ongoing pregnancy</p> <p>Clinical pregnancy</p> <p>Miscarriage</p> <p>Cycle cancellation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 12 trials reported live birth</p> <p>Trial methods limited by lack of blinding</p> <p>Poor reporting of study methods for OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMY731</p> <p><a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a> </p> <p>IVF vs tubal re‐anastomosis (sterilisation reversal) for subfertility after tubal sterilisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tubal re‐anastomosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy Multiple pregnancy</p> <p>Other serious maternal morbidity, (incl OHSS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Empty review with no</p> <p>trials</p> <p>No longer being updated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ZP672</p> <p><a href="./references#CD012103-bbs2-0013" title="PandianZ , GibreelA , BhattacharyaS . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003357.pub3] ">Pandian 2015</a> </p> <p>IVF for unexplained subfertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>733 couples with unexplained subfertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Expectant management</p> <p>Intrauterine insemination Intrauterine insemination +</p> <p>ovarian stimulation</p> <p>Clomiphene citrate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy Multiple pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some evidence was based</p> <p>on a single trial</p> <p>Limitations included imprecision and heterogeneity for some outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LA541</p> <p><a href="./references#CD012103-bbs2-0002" title="AlbuquerqueLET , TsoLO , SaconatoH , AlbuquerqueMCRM , MacedoCR . Depot versus daily administration of gonadotrophin‐releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002808.pub3] ">Albuquerque 2013</a> </p> <p>Depot vs daily administration of GnRHa protocols for pituitary desensitisation in assisted reproduction cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 RCTs,</p> <p>12 for meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1811 couples with any cause of subfertility undergoing IVF with COH with hFSH, hMG or rFSH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pituitary downregulation with depot administration of GnRHa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daily administration of GnRHa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy<sup>a</sup> </p> <p>Miscarriage</p> <p>Multiple pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S tudy quality unclear due to poor reporting. O nly four stu dies reported live birth an d only five described adequate methods for allocation concealment . </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK973</p> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> <p>Recombinant vs urinary gonadotrophin for ovarian stimulation in ART cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9606 normogonadotrophic women undergoing fresh and/or frozen thawed IVF or ICSI cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference reported in moderate/severe OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WPM1780</p> <p><a href="./references#CD012103-bbs2-0011" title="MartinsWP , VieiraADD , FigueiredoJBP , NastriCO . FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010042.pub2] ">Martins 2013</a> </p> <p>FSH replaced by low‐dose hCG in the late follicular phase vs continued FSH for ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>351 women undergoing COH for ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low‐dose hCG instead of FSH in late follicular phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continued FSH in late follicular phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy</p> <p>Miscarriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small studies and low event rate</p> <p>Total OHSS incidence reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHH752</p> <p><a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a> </p> <p>Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing ART </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2596 women of any age with subfertility regardless of cause, undergoing ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pretreatment with combined oral contraceptive pills</p> <p>Pretreatment with progestogens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No pretreatment</p> <p>Placebo</p> <p>Progestogens</p> <p>Oestrogens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy</p> <p>Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 3/23 studies reported on OHSS</p> <p>2 of these 3 studies did not define how they diagnosed the condition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK972</p> <p><a href="./references#CD012103-bbs2-0010" title="KwanI , BhattacharyaS , KangA , WoolnerA . Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005289.pub3] ">Kwan 2014</a> </p> <p>Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>781 women undergoing COH in an IVF/ICSI cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transvaginal ultrasonography + Oestradiol measurement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transvaginal ultrasonography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy</p> <p>Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only total OHSS reported, including mild OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMB1261</p> <p><a href="./references#CD012103-bbs2-0004" title="BoomsmaCM , KeaySD , MacklonNS . Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005996.pub3] ">Boomsma 2012</a> </p> <p>Peri‐implantation glucocorticoid administration for ART cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1879 subfertile patients undergoing IVF/ICSI, regardless of cause of infertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucocorticoids in the peri‐implantation phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No glucocorticoids in the peri‐implantation phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>Multiple pregnancy<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy Miscarriage</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 2 studies, pooled total OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VJP951</p> <p><a href="./references#CD012103-bbs2-0018" title="SiristatidisCS , BasiosG , PergialiotisV , VogiatziP . Aspirin for in vitro fertilisation. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD004832.pub4] ">Siristatidis 2016</a> </p> <p>Aspirin for IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2653 women undergoing IVF/ICSI and their partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aspirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 1 of 13 studies reported on OHSS and without exact numbers or explanation for numerators/denominators </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CS1400</p> <p><a href="./references#CD012103-bbs2-0016" title="SiristatidisCS , MaheshwariA , BhattacharyaS . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006606.pub2] ">Siristatidis 2009</a> </p> <p>In vitro maturation in subfertile women with PCOS undergoing assisted reproduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 women with PCOS and subfertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro maturation + IVF/ICSI in women with PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional IVF/ICSI in women with PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Effectiveness</p> <p>Clinical pregnancy Miscarriage</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Empty review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRS911</p> <p><a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a> </p> <p>Acupuncture and ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4544 women undergoing ART, any type of acupuncture at any time point before, after or during ART, intended to improve ART outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acupuncture of men, women or both during COH</p> <p>Acupuncture + ART</p> <p>Acupuncture alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment</p> <p>Placebo</p> <p>Sham acupuncture</p> <p>Acupuncture + ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No trials reported on OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MHM931</p> <p><a href="./references#CD012103-bbs2-0012" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a> </p> <p>Recombinant luteinising hormone (rLH) for COH in assisted reproductive cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2612 subfertile ovulatory women undergoing IVF or ICSI</p> <p>High risk: NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Combination of rLH and rFSH for COH in IVF/ICSI followed by ET in GnRHa and GnRH antagonist protocols </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rFSH alone for COH in IVF/ICSI followed by ET in GnRHa and GnRH antagonist protocols</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS<sup>a</sup> </p> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy Miscarriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 4/14 trials reported on OHSS</p> <p>Pooled OHSS</p> <p>No GRADE assessment in old version</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KH291</p> <p><a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a> </p> <p>Growth hormone for IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>440 women part of a subfertile couple undergoing IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant growth hormone during conventional IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional IVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy</p> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 4 of 10 RCTs reported on adverse events (which could include OHSS)</p> <p>1 study actually mentioned OHSS (however, no cases); pooled OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD265</p> <p><a href="./references#CD012103-bbs2-0017" title="Siristatidis CharalamposS , GibreelA , BasiosG , MaheshwariA , BhattacharyaS . Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2015, issue 11. [DOI: 10.1002/14651858.CD006919.pub4; CD006919] ">Siristatidis 2015</a> </p> <p>GnRHa protocols for pituitary suppression in assisted reproduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3872 women/couples with all types of infertility undergoing ART and using GnRHa for pituitary downregulation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long protocol</p> <p>Long luteal protocol</p> <p>Short protocol</p> <p>Dose continued</p> <p>Dose continued after hCG administration</p> <p>Pretreatment 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short protocol</p> <p>Ultrashort protocol</p> <p>Long follicular phase protocol</p> <p>Ultrashort protocol</p> <p>Dose stopped</p> <p>Dose reduced</p> <p>Dose discontinued after hCG administration</p> <p>Pretreatment 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>OHSS</p> <p>Clinical pregnancy Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 2 of 37 included RCTs reported on OHSS for 2 of 9 compared regimens</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>JC1630</p> <p><a href="./references#CD012103-bbs2-0015" title="ShowellMG , BrownJ , ClarkeJ , HartRJ . Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD007807.pub2] ">Showell 2013</a> </p> <p>Antioxidants for female subfertility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3548 subfertile women referred to fertility clinic who might or might not undergo ART (IVF, ICSI or IUI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant antioxidants in females</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment</p> <p>Placebo</p> <p>Another antioxidant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth<sup>a</sup> </p> <p>Clinical pregnancy Miscarriage</p> <p>Multiple pregnancy</p> <p>Adverse effects (incl OHSS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 3 studies reported: 1 no data and 2 no cases</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Primary review outcome. </p> <p>ART: artifical reproductive technology.</p> <p>COH: controlled ovarian hyperstimulation.</p> <p>ET: embryo transfer.</p> <p>FSH: follicle‐stimulating hormone.</p> <p>GnRHa: gonadotrophin‐releasing hormone agonist.</p> <p>hCG: human chorionic gonadotrophin.</p> <p>HES: hydroxyethyl starch.</p> <p>hFSH: human follicle‐stimulating hormone.</p> <p>hMG: human menopausal gonadotrophin.</p> <p>ICSI: intracytoplasmic sperm injection.</p> <p>IUI: intrauterine insemination.</p> <p>IVF: in vitro fertilisation.</p> <p>LH: luteinising hormone.</p> <p>NA: not applicable.</p> <p>OHSS: ovarian hyperstimulation syndrome.</p> <p>PCOS: polycystic ovary syndrome.</p> <p>RCT: randomised controlled trial.</p> <p>rFSH: recombinant follicle‐stimulating hormone.</p> <p>rLH: recombinant luteinising hormone.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Review characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012103-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Last search date assessment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Review no.</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>First review author</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review title</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Date last assessed <br/> up to date</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&lt; 3 years since last assessed up to date or deemed stable</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embryo freezing for preventing OHSS</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/11/2010</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stable</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA 563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coasting (withholding of gonadotrophins) for preventing OHSS</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/07/2010</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TH1338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dopamine agonists for preventing OHSS</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/08/2016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMA481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume expanders for prevention of OHSS</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/09/2016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant vs urinary hCG for final oocyte maturation triggering in IVF and ICSI cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/04/2015</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MM1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GnRHa vs hCG for oocyte triggering in antagonist‐assisted reproductive technology</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>08/09/2014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LDT1201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metformin treatment before and during IVF or ICSI in women with PCOS</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/10/2014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AWP1710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH vs daily FSH for women undergoing assisted reproduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/06/2015</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate in combination with gonadotrophins for controlled ovarian stimulation in women undergoing IVF </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/03/2012</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TA1860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0003" title="AllersmaT , FarquharC , CantineauAEP . Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010550.pub2] ">Allersma 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Natural cycle IVF for subfertile couples</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/03/2013</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MV263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden</a><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/11/2014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotrophin‐releasing hormone antagonists for ART</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/04/2016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMY731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IVF vs tubal re‐anastomosis (sterilisation reversal) for subfertility after tubal sterilisation </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/05/2009</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Empty, stable</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ZP672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0013" title="PandianZ , GibreelA , BhattacharyaS . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003357.pub3] ">Pandian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IVF for unexplained subfertility</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/05/2015</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LA541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0002" title="AlbuquerqueLET , TsoLO , SaconatoH , AlbuquerqueMCRM , MacedoCR . Depot versus daily administration of gonadotrophin‐releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002808.pub3] ">Albuquerque 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depot vs daily administration of GnRHa protocols for pituitary desensitisation in assisted reproduction<br/> cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/07/2012</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant vs urinary gonadotrophin for ovarian stimulation in ART cycles</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/10/2010</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WPM1780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0011" title="MartinsWP , VieiraADD , FigueiredoJBP , NastriCO . FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010042.pub2] ">Martins 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH replaced by low‐dose hCG in late follicular phase vs continued FSH for ART</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/02/2013</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHH752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing ART </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/11/2008</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0010" title="KwanI , BhattacharyaS , KangA , WoolnerA . Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005289.pub3] ">Kwan 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/05/2014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMB1261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0004" title="BoomsmaCM , KeaySD , MacklonNS . Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005996.pub3] ">Boomsma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peri‐implantation glucocorticoid administration for ART cycles</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/09/2011</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VJP951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0018" title="SiristatidisCS , BasiosG , PergialiotisV , VogiatziP . Aspirin for in vitro fertilisation. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD004832.pub4] ">Siristatidis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aspirin for IVF</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/05/2016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CS1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0016" title="SiristatidisCS , MaheshwariA , BhattacharyaS . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006606.pub2] ">Siristatidis 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro maturation in subfertile women with PCOS undergoing assisted reproduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/02/2011</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Empty</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRS911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acupuncture and ART</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/07/2013</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MHM931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0012" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant luteinising hormone (rLH) for COH in assisted reproductive cycles</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/01/2007</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KH291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Growth hormone for IVF</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/07/2009</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0017" title="Siristatidis CharalamposS , GibreelA , BasiosG , MaheshwariA , BhattacharyaS . Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2015, issue 11. [DOI: 10.1002/14651858.CD006919.pub4; CD006919] ">Siristatidis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GnRHa protocols for pituitary suppression in assisted reproduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/04/2015</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>JC1630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0015" title="ShowellMG , BrownJ , ClarkeJ , HartRJ . Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD007807.pub2] ">Showell 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antioxidants for female subfertility</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/04/2014</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ART: artifical reproductive technology.</p> <p>COH: controlled ovarian hyperstimulation.</p> <p>FSH: follicle‐stimulating hormone.</p> <p>GnRHa: gonadotrophin‐releasing hormone agonist.</p> <p>hCG: human chorionic gonadotrophin.</p> <p>ICSI: intracytoplasmic sperm injection.</p> <p>IUI: intrauterine insemination.</p> <p>IVF: in vitro fertilisation.</p> <p>OHSS: ovarian hyperstimulation syndrome.</p> <p>PCOS: polycystic ovary syndrome.</p> <p>rLH: recombinant luteinising hormone.</p> <p>✔ under 3 years since last assessed as up to date</p> <p><b>X</b> over 3 years since last assessed as up to date </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Last search date assessment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012103-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">AMSTAR assessment per review</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Review no.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>First review author + year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Review title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AMSTAR criteria</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prespecified question and inclusion criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duplicate study selection and data extraction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comprehensive literature search</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grey literature included</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lists included and excluded studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Describes characteristics of included studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study quality assessed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies combined using appropriate methods</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Likelihood of publication bias considered/tested</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Potential for conflict of interest addressed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embryo freezing for preventing ovarian hyperstimulation syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADA 563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TH1338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dopamine agonists for preventing ovarian hyperstimulation syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMA481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume expanders for the prevention of ovarian hyperstimulation syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MM1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotropin‐releasing hormone agonist versus hCG for oocyte triggering in antagonist‐assisted reproductive technology </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LDT1201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AWP1710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH versus daily FSH for women undergoing assisted reproduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AM1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate in combination with gonadotrophins for controlled ovarian stimulation in women undergoing in vitro fertilisation </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TA1860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0003" title="AllersmaT , FarquharC , CantineauAEP . Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010550.pub2] ">Allersma 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Natural cycle IVF for subfertile couples</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MV263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HA412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AMY731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro fertilisation versus tubal re‐anastomosis (sterilisation reversal) for subfertility after tubal sterilisation </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ZP672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0013" title="PandianZ , GibreelA , BhattacharyaS . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003357.pub3] ">Pandian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro fertilisation for unexplained subfertility</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LA541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0002" title="AlbuquerqueLET , TsoLO , SaconatoH , AlbuquerqueMCRM , MacedoCR . Depot versus daily administration of gonadotrophin‐releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002808.pub3] ">Albuquerque 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depot versus daily administration of gonadotrophin‐releasing hormone<br/> agonist protocols for pituitary desensitisation in assisted reproduction<br/> cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WPM1780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0011" title="MartinsWP , VieiraADD , FigueiredoJBP , NastriCO . FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010042.pub2] ">Martins 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHH752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOK972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0010" title="KwanI , BhattacharyaS , KangA , WoolnerA . Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005289.pub3] ">Kwan 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMB1261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0004" title="BoomsmaCM , KeaySD , MacklonNS . Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005996.pub3] ">Boomsma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VJP951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0018" title="SiristatidisCS , BasiosG , PergialiotisV , VogiatziP . Aspirin for in vitro fertilisation. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD004832.pub4] ">Siristatidis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aspirin for in vitro fertilisation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CS1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0016" title="SiristatidisCS , MaheshwariA , BhattacharyaS . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006606.pub2] ">Siristatidis 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IRS911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acupuncture and assisted reproductive technology</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MHM931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0012" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant luteinising hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KH291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Growth hormone for in vitro fertilisation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0017" title="Siristatidis CharalamposS , GibreelA , BasiosG , MaheshwariA , BhattacharyaS . Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2015, issue 11. [DOI: 10.1002/14651858.CD006919.pub4; CD006919] ">Siristatidis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>JC1630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0015" title="ShowellMG , BrownJ , ClarkeJ , HartRJ . Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD007807.pub2] ">Showell 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antioxidants for female subfertility</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✔</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p>Search date: 24/07/2016.</p> <p>ART: artifical reproductive technology.</p> <p>FSH: follicle‐stimulating hormone.</p> <p>hCG: human chorionic gonadotrophin.</p> <p>ICSI: intracytoplasmic sperm injection.</p> <p>IUI: intrauterine insemination.</p> <p>IVF: in vitro fertilisation.</p> <p>NA: not applicable.</p> <p>rLH: recombinant luteinising hormone.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">AMSTAR assessment per review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012103-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of findings for OHSS: per review and/or per intervention</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review title and</b> </p> <p><b>comparison intervention/control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> <p><b>with intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> <p><b>(studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence</b> </p> <p><b>(GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embryo freezing for preventing ovarian hyperstimulation syndrome</p> <p><i>(Embryo freezing vs fresh transfer)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 60 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 125 per 1000</p> <p>(62 to 240)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.12</p> <p>(0.01 to 2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Evidence based on a single open‐label study with insufficient methodological details provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0006" title="D'AngeloA , AmsoNN . Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002806.pub2] ">D'Angelo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embryo freezing for preventing ovarian hyperstimulation syndrome</p> <p><i>(Embryo freezing vs intravenous albumin)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS:</p> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS:</p> <p>308 per 1000</p> <p>(41 to 824)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 5.33</p> <p>(0.51 to 56.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Evidence based on a single open‐label trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0007" title="D'AngeloA , BrownJ , AmsoNN . Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002811.pub3] ">D'Angelo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS:</p> <p>265 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS:</p> <p>58 per 1000</p> <p>(11 to 241)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.17</p> <p>(0.03 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Evidence based on a single conference abstract<br/> Insufficient methodological details provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0020" title="TangH , MouradS , ZhaiSD , HartRJ . Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008605.pub3] ">Tang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dopamine agonists for preventing ovarian hyperstimulation syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or severe OHSS: 286 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or severe OHSS: 97 per 1000</p> <p>(71 to 135)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.27</p> <p>(0.19 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2091</p> <p>(16 studies))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Lack of details for allocation concealment and blinding, selective reporting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume expanders for the prevention of ovarian hyperstimulation syndrome</p> <p><i>(human albumin vs placebo/no treatment)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or severe OHSS:</p> <p>122 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or severe OHSS: 85 per 1000 (61 to 177)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0,67</p> <p>(0.47 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1452</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Lack of details on allocation concealment and selective reporting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume expanders for the prevention of ovarian hyperstimulation syndrome</p> <p><i>(HES vs placebo)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS: 164 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS: 50 per 1000</p> <p>(23 to 104)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.27</p> <p>(0.12 to 0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Lack of details on allocation concealment and selective reporting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0027" title="YoussefMA , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD001302.pub3] ">Youssef 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume expanders for the prevention of ovarian hyperstimulation syndrome</p> <p><i>(mannitol vs placebo)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS: 517 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or</p> <p>severe OHSS: 289 per 1000</p> <p>(191 to 407)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.38</p> <p>(0.22 to 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Lack of details on allocation concealment and selective reporting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles <i>(r‐hCG vs u‐hCG)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 27 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:40 per 1000</p> <p>(15 to 102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.39</p> <p>(0.25 to 0.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>374</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>One of the trials lacked methodological details on randomisation, allocation concealment and blinding </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0026" title="YoussefMA , Abou‐SettaAM , LamWS . Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003719.pub4] ">Youssef 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles <i>(r‐LH vs u‐hCG)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 10 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>17 per 1000</p> <p>(11 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.76</p> <p>(0.37 to 8.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>417</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>One of the trials lacked adequate methodological details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0025" title="YoussefMAFM , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotropin‐releasing hormone agonist versus hCG for oocyte triggering in antagonist‐assisted reproductive technology </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 5 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>1 per 1000</p> <p>(0 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.15</p> <p>(0.05 to 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>989</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>All studies at high risk of bias in 1 or more domains</p> <p>None clearly reported blinded outcome assessment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0021" title="TsoLO , CostelloMF , AlbuquerqueLET , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 270 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 97 per 1000</p> <p>(62 to 153)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.29</p> <p>(0.18 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>798</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH versus daily FSH for women undergoing assisted reproduction</p> <p>(<i>low dose</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 47 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 57 per 1000</p> <p>(26 to 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.22</p> <p>(0.56 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>645</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH versus daily FSH for women undergoing assisted reproduction</p> <p>(<i>medium dose</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 63 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 60 per 1000 (45 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.96</p> <p>(0.68 to 1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3075</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Confidence intervals compatible with clinically meaningful benefit in either arm or with no effect, plus high risk of attrition bias in 2 studies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0014" title="PouwerAW , FarquharC , KremerJAM . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009577.pub3] ">Pouwer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐acting FSH versus daily FSH for women undergoing assisted reproduction</p> <p>(<i>high dose</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.73</p> <p>(0.09 to 32.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>High risk of attrition bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0009" title="GibreelA , MaheshwariA , BhattacharyaS . Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD008528.pub2] ">Gibreel 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation </p> <p><i>(clomiphene + gonadotropins vs gonadotropins)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 50 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:12 per 1000</p> <p>(5 to 27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.23</p> <p>(0.1 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1559</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Very wide 95% confidence interval crossing the threshold points of appreciable benefit or harm, which is 25% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0003" title="AllersmaT , FarquharC , CantineauAEP . Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010550.pub2] ">Allersma 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Natural cycle IVF for subfertile couples</p> <p><i>(natural cycle vs conventional IVF)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 67 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>13 per 1000</p> <p>(1 to 393)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.10</p> <p>(0.01 to 4.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Only 1 study reporting on OHSS</p> <p>Allocation concealment method not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> <p><i>(hCG versus placebo/no treatment)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 41 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>155 per 100</p> <p>(76 to 292)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 4.28</p> <p>(1.191 to 9.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>387</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Poor reporting of study methods</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> <p><i>(progesterone vs hCG regimens)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 126 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 72 per 1000</p> <p>(31 to 162)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.54</p> <p>(0.22 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>615</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Poor reporting of study methods</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> <p><i>(progesterone + GnRH agonist)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 50 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 50 per 1000</p> <p>(17 to 137)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.00</p> <p>(0.33 to 3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Poor reporting of study methods</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0022" title="van derLindenM , BuckinghamK , FarquharC , KremerJAM , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD009154.pub3] ">van der Linden 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteal phase support for ART cycles</p> <p><i>(progesterone vs progesterone + oestrogens)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 39 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 22 per 1000</p> <p>(8 to 62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.56</p> <p>(0.2 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Poor reporting of study methods</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0001" title="Al‐InanyHG , YoussefMAFM , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology</p> <p><i>(GnRH antagonist vs GnRH agonist)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 114 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 73 per 1000</p> <p>(62 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.61<br/> (0.51 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7944</p> <p>(36 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methodological limitations including poor allocation concealment and lack of blinding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0024" title="YossryM , AboulgharM , D'AngeloA , GillettW . In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004144.pub2] ">Yossry 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation </p> <p><i>(IVF vs tubal reanastomosis)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Empty review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0013" title="PandianZ , GibreelA , BhattacharyaS . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003357.pub3] ">Pandian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro fertilisation for unexplained subfertility</p> <p><i>(IVF vs IUI + gonadotropins/clomiphene citrate)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 58 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 66 per 1000</p> <p>(26 to 158)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.15 (0.43 to 3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Only 2 studies on OHSS reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0002" title="AlbuquerqueLET , TsoLO , SaconatoH , AlbuquerqueMCRM , MacedoCR . Depot versus daily administration of gonadotrophin‐releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002808.pub3] ">Albuquerque 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles </p> <p><i>(depot vs daily gonadotropins)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 3 per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 2 per 100<br/> (1 to 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.84<br/> (0.29 to 2.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>570</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most studies were classified as at unclear risk of bias for all domains</p> <p>Imprecision, number of events &lt; 300<br/> Studies were insufficient to assess publication bias </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles </p> <p><i>(rFSH vs HMG/HMG‐HP)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 17 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 17 per 1000</p> <p>(10 to 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.00</p> <p>(0.58 to 1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3197</p> <p>(11 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles </p> <p><i>(rFSH vs FSH‐P)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 28 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:49 per 1000</p> <p>(25 to 95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.79</p> <p>(0.89 to 3.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1490</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles </p> <p><i>(rFSH vs FSH‐HP)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 28 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>31 per 1000</p> <p>(20 to 48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.11</p> <p>(0.70 vs 1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3053</p> <p>(14 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two additional trials excluded in sensitivity analyses because it was unclear if data were reported according to ITT analysis (those were included for "Overall OHSS") </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0023" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , Al‐InanyHG . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles </p> <p><i>(rec‐hCG vs u‐hCG)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 19 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>22 per 1000</p> <p>(16 to 30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.18 (0.86 vs 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7740</p> <p>(32 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0011" title="MartinsWP , VieiraADD , FigueiredoJBP , NastriCO . FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010042.pub2] ">Martins 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques </p> <p><i>(low‐dose hCG vs FSH in late follicular phase)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 3 per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 1 per 100</p> <p>(0 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.30 (0.06 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>351</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Inconsistency, high risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral contraceptive pill, progestogen or oestrogen pre‐ treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques </p> <p><i>(OAC plus antagonist vs antagonist)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 17 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 25 per 1000</p> <p>(5 to 133)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.5 (0.26 to 8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single study reporting on OHSS</p> <p>Imprecision, number of events &lt; 300</p> <p>Wide confidence intervals that cross line of no effect</p> <p>High risk of attrition bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0019" title="SmuldersB , vanOirschotSM , FarquharC , RombautsL , KremerJAM . Oral contraceptive pill, progestogen or estrogen pre‐treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2] ">Smulders 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral contraceptive pill, progestogen or oestrogen pre‐ treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques </p> <p><i>(OAC plus antagonist vs agonist)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 55 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 35 per 1000</p> <p>(12 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.63</p> <p>(0.21 to 1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>One study at high risk of attrition bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0010" title="KwanI , BhattacharyaS , KangA , WoolnerA . Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005289.pub3] ">Kwan 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Monitoring of stimulated cycles in assisted reproduction</p> <p>(IVF and ICSI)</p> <p><i>(transvaginal ultrasound + estradiol vs transvaginal ultrasound)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 36 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 36 per 1000</p> <p>(18 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.03</p> <p>(0.48 to 2.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>781</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300 with wide confidence intervals</p> <p>Methods of randomisation inadequately described in 3 of 6 trials, allocation concealment inadequately described in all 6 trials and blinding inadequately described in 5 of 6 trials </p> <p>No definition of OHSS provided by authors of these 6 studies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0004" title="BoomsmaCM , KeaySD , MacklonNS . Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005996.pub3] ">Boomsma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles </p> <p><i>(adjuvant glucocorticoids vs no glucocorticoids)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 194 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 159 per 1000</p> <p>(64 to 392)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.82 (0.33 to 2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0018" title="SiristatidisCS , BasiosG , PergialiotisV , VogiatziP . Aspirin for in vitro fertilisation. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD004832.pub4] ">Siristatidis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aspirin for in vitro fertilisation</p> <p><i>(aspirin vs no treatment/placebo)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 1 study reported on OHSS; no exact numbers or explanation of numerators/denominators given </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0016" title="SiristatidisCS , MaheshwariA , BhattacharyaS . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006606.pub2] ">Siristatidis 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction </p> <p><i>(IVM vs conventional IVF)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Empty review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0005" title="CheongYC , DixS , Hung Yu NgE , LedgerWL , FarquharC . Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3] ">Cheong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acupuncture and assisted reproductive technology</p> <p><i>(acupuncture vs no acupuncture/sham acupuncture)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies reported on OHSS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0012" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles </p> <p><i>(combined rLH + FSH vs FSH )</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 20 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS:</p> <p>27 per 1000</p> <p>(12 to 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.34</p> <p>(0.58 to 3.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>986</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Some methodological details unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0008" title="DuffyJMN , AhmadG , MohiyiddeenL , NardoLG , WatsonA . Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] ">Duffy 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Growth hormone for in vitro fertilization</p> <p><i>(growth hormone vs no treatment/placebo)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 1 study reported on OHSS; however, no cases of OHSS were reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0017" title="Siristatidis CharalamposS , GibreelA , BasiosG , MaheshwariA , BhattacharyaS . Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2015, issue 11. [DOI: 10.1002/14651858.CD006919.pub4; CD006919] ">Siristatidis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gonadotropin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction </p> <p><i>(different protocols vs other protocol)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 20 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall OHSS: 27 per 1000</p> <p>(12 to 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.34</p> <p>(0.58 to 3.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>986</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision, number of events &lt; 300</p> <p>Some methodological details unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012103-bbs2-0015" title="ShowellMG , BrownJ , ClarkeJ , HartRJ . Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD007807.pub2] ">Showell 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antioxidants for female subfertility</p> <p><i>(antioxidants vs no treatment/placebo/other antioxidant)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Although 3 studies reported on OHSS, no numbers were given, so effect size could not be calculated </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Review authors GRADED these outcomes as 'high quality'; however, the total event rate &lt; 300 would justify downgrading for this to moderate‐quality evidence. </p> <p>ART: artifical reproductive technology.</p> <p>FSH: follicle‐stimulating hormone.</p> <p>FSH‐HP: highly purified FSH.</p> <p>hCG: human chorionic gonadotrophin.</p> <p>HES: hydroxyethyl starch.</p> <p>ICSI: intracytoplasmic sperm injection.</p> <p>IUI: intrauterine insemination.</p> <p>IVF: in vitro fertilisation.</p> <p>IVM: in vitro maturation.</p> <p>NA: not applicable.</p> <p>OAC: oral anticoagulant.</p> <p>OHSS: ovarian hyperstimulation syndrome.</p> <p>OR: odds ratio.</p> <p>rFSH: recombinant follicle‐stimulating hormone.</p> <p>r‐hCG: recombinant human chorionic gonadotrophin.</p> <p>rLH: recombinant luteinising hormone.</p> <p>Total: any grade of OHSS.</p> <p>u‐hCG: urinary human chorionic gonadotrophin.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of findings for OHSS: per review and/or per intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012103.pub2/full#CD012103-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012103.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012103-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012103-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD012103-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012103-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012103\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012103\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012103\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012103\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012103\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012103.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012103.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012103.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012103.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012103.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729532968"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012103.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729532972"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012103.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918edf335987bd65',t:'MTc0MDcyOTUzMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 